<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8532523</article-id><article-id pub-id-type="pmcid-ver">PMC8532523.1</article-id><article-id pub-id-type="pmcaid">8532523</article-id><article-id pub-id-type="pmcaiid">8532523</article-id><article-id pub-id-type="pmid">34691042</article-id><article-id pub-id-type="doi">10.3389/fimmu.2021.734471</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Cui</surname><given-names initials="X">Xinle</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1392064"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Snapper</surname><given-names initials="CM">Clifford M.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>The Institute for Vaccine Research and Department of Pathology, Uniformed Services University of the Health Sciences</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Citranvi Biosciences LLC</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lawrence S. Young, University of Warwick, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Lisa Stockdale, University of Oxford, United Kingdom; Rupsa Basu, Helaina Inc., United States</p></fn><corresp id="fn001">*Correspondence: Xinle Cui, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:xinle.cui@nih,gov">xinle.cui@nih,gov</email>; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:jamescui2018@gmail.com">jamescui2018@gmail.com</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">375200</issue-id><elocation-id>734471</elocation-id><history><date date-type="received"><day>01</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>23</day><month>10</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-04 12:25:14.050"><day>04</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Cui and Snapper</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Cui and Snapper</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-12-734471.pdf"/><abstract><p>Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths world-wide. EBV is also the primary cause of infectious mononucleosis, and up to 70% of adolescents and young adults in developed countries suffer from infectious mononucleosis. In addition, EBV has been shown to play a critical role in the pathogenesis of multiple sclerosis. An EBV prophylactic vaccine that induces neutralizing antibodies holds great promise for prevention of EBV associated diseases. EBV envelope proteins including gH/gL, gB and gp350 play key roles in EBV entry and infection of target cells, and neutralizing antibodies elicited by each of these proteins have shown to prevent EBV infection of target cells and markedly decrease EBV titers in the peripheral blood of humanized mice challenged with lethal dose EBV. Recent studies demonstrated that immunization with the combination of gH/gL, gB and/or gp350 induced markedly increased synergistic EBV neutralizing activity compared to immunization with individual proteins. As previous clinical trials focused on gp350 alone were partially successful, the inclusion of gH/gL and gB in a vaccine formulation with gp350 represents a promising approach of EBV prophylactic vaccine development. Therapeutic EBV vaccines have also been tested clinically with encouraging results. Immunization with various vaccine platforms expressing the EBV latent proteins EBNA1, LMP1, and/or LMP2 promoted specific CD4+ and CD8+ cytotoxic responses with anti-tumor activity. The addition of EBV envelope proteins gH/gL, gB and gp350 has the potential to increase the efficacy of a therapeutic EBV vaccine. The immune system plays a critical role in the control of tumors, and immune cell therapy has emerged as a promising treatment of cancers. Adoptive T-cell therapy has been successfully used in the prevention and treatment of post-transplant lymphoproliferative disorder. Chimeric antigen receptor T cell therapy and T cell receptor engineered T cell therapy targeting EBV latent proteins LMP1, LMP2 and/or EBNA1 have been in development, with the goal to increase the specificity and efficacy of treatment of EBV associated cancers.</p></abstract><kwd-group><kwd>Epstein-Barr virus</kwd><kwd>EBV-associated cancer</kwd><kwd>EBV prophylactic vaccine</kwd><kwd>therapeutic EBV vaccine</kwd><kwd>adoptive T-cell therapy</kwd><kwd>chimeric antigen receptor T cell therapy</kwd><kwd>T cell receptor engineered T cell therapy</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Uniformed Services University of the Health Sciences
</institution><institution-id institution-id-type="doi">10.13039/100007188</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">Dean&#8217;s Research and Education Endowment Fund</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>National Cancer Institute
</institution><institution-id institution-id-type="doi">10.13039/100000054</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn002">Intramural Research Program </award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="224"/><page-count count="16"/><word-count count="7987"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Epstein-Barr virus (EBV) is a gamma human herpesvirus that primarily infects B cells and epithelial cells. EBV is the primary cause of infectious mononucleosis (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). There are ~125,000 new cases of infectious mononucleosis each year in the United States, and it is the most common cause of lost time for new Army recruits (<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>). Infectious mononucleosis could cause persistent fatigue for up to 6 months and cause severe neurologic, hematologic, or liver complications (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). EBV is also the first human tumor virus discovered, and it has been strongly implicated in the etiology of multiple lymphoid and epithelial cancers, such as Burkitt lymphoma (BL), Hodgkin lymphoma (HL), post-transplant lymphoproliferative disorder (PTLD), nasopharyngeal carcinoma (NPC), and gastric carcinoma (GC) (<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>). Overall EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths world-wide each year (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Patients undergoing solid organ or stem cell transplantation are at risk of developing uncontrolled B cell proliferation due to EBV reactivation, termed PTLD that can evolve into Hodgkin lymphoma or non-Hodgkin lymphoma, and a similar phenomenon also occurs in patients with AIDS (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). A role for EBV has also been suggested in the pathogenesis of T and NK cell lymphomas, aggressive NK cell leukemia, and lymphoepithelioma-like carcinoma of the lung, salivary gland and thymus (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>). Many studies further suggest a possible role for EBV in the pathogenesis of several autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis and Sjogren&#8217;s syndrome (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B18" ref-type="bibr">18</xref>). In addition, there is evidence suggesting that childhood EBV infection in sub-Saharan Africa may worsen the clinical course of malaria (<xref rid="B19" ref-type="bibr">19</xref>). It has also been proposed that EBV infection in the oral cavity may play an important role in promoting chronic periodontitis (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>EBV prophylactic vaccine aiming at prevention of primary EBV infection has been in development for more than 30 years, and clinical trials of therapeutic EBV vaccines targeting EBV associated cancers have been conducted for more than 10 years. Though neither an EBV prophylactic vaccine nor a therapeutic EBV vaccine has been licensed, promising progresses have been made. Encouraged by the spectacular results of CAR-T cell therapy targeting B cell antigens, CAR-T cell therapy and TCR engineered T cell therapy targeting EBV antigens are in development, with the goal of development of highly efficient treatment for EBV associated cancers and avoid the adverse effects of targeting B cell antigen.</p></sec><sec id="s2"><title>Epstein-Barr Virus</title><p>EBV has a linear, double-stranded DNA genome that is approximately 170 kilobase pairs in length, which encodes more than 80 proteins and 46 functional small untranslated RNAs (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). EBV is typically transmitted <italic toggle="yes">via</italic> saliva and contracted during infancy in developing countries, whereas in the developed world, it is typically contracted during adolescence (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B23" ref-type="bibr">23</xref>). EBV infects &gt;95% of the world population by adulthood. The target cells of EBV are B lymphocytes and epithelial cells, and the mechanism by which EBV enters into host cells is shared in many aspects by other members of the herpesvirus family (<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>). Infection of B cells with EBV is initiated by binding of the EBV envelope protein gp350 to the complement receptor 2 (CR2)/CD21. Upon binding to B cell CR2, EBV gp42 interacts with the host cell surface MHC-II, leading to its association with the heterodimeric protein gH/gL. EBV gH/gL then activates the EBV fusion protein gB, that directly mediates viral-host cell endosomal membrane fusion [(<xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>), <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1A</bold>
</xref>]. EBV infection of epithelial cells involves EBV BMRF2 binding to integrins, followed by gH/gL binding to integrins and ephrin receptor A2, triggering activation of gB and fusion of the viral envelope to the plasma membrane of the epithelial cell [(<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B28" ref-type="bibr">28</xref>&#8211;<xref rid="B36" ref-type="bibr">36</xref>), <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1B</bold>
</xref>]. Thus, EBV envelope glycoproteins gH/gL, gB and gp350 play key roles in EBV infection of target cells, where gH/gL and gB constitute the &#8220;core fusion machinery&#8221; mediating fusion with the cell membrane (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>). The native conformation of EBV gB is a trimer, and EBV gH and gL naturally form a heterodimer (<xref rid="B24" ref-type="bibr">24</xref>). EBV envelope proteins gH/gL and gB are essential for EBV infection of both B cells and epithelial cells, whereas gp350 is important for efficient infection of B cells (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B33" ref-type="bibr">33</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>EBV entry and infection of target cells. <bold>(A)</bold> EBV infection of B cells. <bold>(B)</bold> EBV infection of epithelial cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-12-734471-g001.jpg"/></fig><p>Once infecting the host, EBV establishes two alternative modes of infection: lytic and latent. During the lytic infection, EBV expresses more than 80 lytic proteins and these proteins facilitate the generation of new EBV viral particles and engage in immune evasion (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). During the process of developing latency, EBV progresses through three different EBV latency programs characterized by a set of gradually restricted viral gene expression patterns, but no production of EBV virions. Through this process EBV develops eventual lifetime persistence in memory B cells (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Latent EBV infections play a key role in the pathogenesis of EBV associated cancer. In type III latency, all eight EBV latent antigens are expressed, including six EBV nuclear antigens (EBNA 1, EBNA2, EBNA3A, EBNA3B, EBNA 3C and EBNA 6/LP), and two latent membrane proteins (LMP1 and LMP2) (<xref rid="B21" ref-type="bibr">21</xref>). Latency III is mainly seen in PTLD and immunoblastic lymphomas in HIV infected patients (<xref rid="B41" ref-type="bibr">41</xref>). Latency II exists in HL, NPC and GC, where EBNA1, LMP1 and LMP2 are expressed (<xref rid="B42" ref-type="bibr">42</xref>). In type I latency, only EBNA1 is expressed and is seen in BL (<xref rid="B21" ref-type="bibr">21</xref>).</p></sec><sec id="s3"><title>EBV Infection and Infectious Mononucleosis</title><p>EBV is found in saliva, and is transmitted through kissing, coughing, intimate intact or sharing food and eating utensils (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). After successful transmission, EBV infects oral epithelial cells, most likely squamous epithelial cells in the tonsil (<xref rid="B45" ref-type="bibr">45</xref>). EBV also infects B cells in the lymphatic tissues of Waldeyer&#8217;s Ring including the tonsils (<xref rid="B44" ref-type="bibr">44</xref>). It is unknown whether epithelial cells or B cells are infected first. EBV replication occurs exclusively in epithelial cells which are thus responsible for EBV transmission. Epithelial cells lack MHC-II so are unable to sequester gp42 upon release of EBV virions. These virions expressing gp42, then demonstrate a preference for infection of B cells, which express MHC-II. Likewise, the presence of gp42 blocks gH binding to integrins on epithelial cells thus inhibiting epithelial cell infection. When released from B cells, MHC-II sequesters gp42 thus producing EBV virions lacking gp42 and demonstrating a preference for infecting epithelial cells (<xref rid="B25" ref-type="bibr">25</xref>). In developing countries primary EBV infection usually occurs during infancy and childhood with most individuals infected by 4 years of age. In contrast, in developed countries, primary EBV infection typically occurs during adolescence or early adulthood. These differences are most likely caused by socioeconomic factors (<xref rid="B44" ref-type="bibr">44</xref>).</p><p>Primary EBV infection in young children usually produces no significant symptoms, whereas primary EBV infection in adolescents and young adults could cause infectious mononucleosis (IM), and up to 70% of adolescents and young adults present with the classical symptoms of IM after EBV infection (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>). IM is characterized by two to four weeks of fever, pharyngitis, cervical lymphadenopathy and fatigue accompanied by a massive expansion of the number of EBV-specific CD8+ T cells after an incubation period of about six weeks (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Disease severity and duration of IM correlate with CD8+ T cell counts rather than with the viral kinetics (<xref rid="B48" ref-type="bibr">48</xref>&#8211;<xref rid="B50" ref-type="bibr">50</xref>). This indicates that IM is caused by an overreaction of the immune system due to a failure in early control of viral replications, leading to an exaggerated CD8+ T cell response with consequent inflammatory cytokine release (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B51" ref-type="bibr">51</xref>). It has been suggested that infants and children, but not older individuals produce an NK cell subset important for early EBV control, thus preventing the occurrence of IM in this population (<xref rid="B52" ref-type="bibr">52</xref>). The vast majority of IM cases are self-limiting with an excellent prognosis, with rare cases of severe acute complications such as splenic rupture, hepatitis and airway obstruction due to tonsil enlargement (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B53" ref-type="bibr">53</xref>). Late complications to IM include Hodgkin lymphoma and multiple sclerosis (<xref rid="B21" ref-type="bibr">21</xref>). Life-long latent EBV infection establishes following primary infection (<xref rid="B41" ref-type="bibr">41</xref>).</p></sec><sec id="s4"><title>EBV Associated Cancers</title><p>EBV is the first human tumor virus identified. EBV not only causes infectious mononucleosis, it is also strongly associated with epithelial cell cancers such as nasopharyngeal cancer (NPC), gastric cancer as well as lymphoid cancers such as Burkitt lymphoma (BL), Hodgkin lymphoma (HL) and post transplantation lymphoproliferative disorder (PTLD) (<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). NPC is endemic in southeast Asia, and the vast majority are the nonkeratinized type, accounting for 80,000 new cases each year worldwide (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B54" ref-type="bibr">54</xref>). Nonkeratinized NPC displays a lymphoepithelial-like (LEL) appearance with a marked lymphocytic infiltration, which is 100% EBV positive (<xref rid="B41" ref-type="bibr">41</xref>). About 10% of gastric cancers are associated with EBV infection, have a similar LEL pathological change and are EBV positive, accounting for about 83,000 new cases each year (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). Essentially all Burkitt lymphoma in equatorial Africa and in Papua New Guinea, are EBV genome-positive, accounting for 7,000 new cases each year (<xref rid="B57" ref-type="bibr">57</xref>&#8211;<xref rid="B59" ref-type="bibr">59</xref>). Hodgkin lymphoma is also strongly associated with EBV, especially the mixed cellularity subtype, of which 80-90% are EBV positive (<xref rid="B60" ref-type="bibr">60</xref>&#8211;<xref rid="B63" ref-type="bibr">63</xref>). PTLD is another example that EBV plays a critical role in cancer pathogenesis, all the cases of PTLD are EBV positive, and adoptive transfer of EBV specific T cells could prevent or cure the disease (<xref rid="B64" ref-type="bibr">64</xref>&#8211;<xref rid="B68" ref-type="bibr">68</xref>). The role of EBV in cancer pathogenesis has also been confirmed in animal models, as inoculation of cotton top tamarins or humanized mice with high titers of EBV results in the development of B-cell lymphomas and lymphoproliferative disease that are seen in humans (<xref rid="B69" ref-type="bibr">69</xref>&#8211;<xref rid="B78" ref-type="bibr">78</xref>).</p><sec id="s4_1"><title>Burkitt&#8217;s Lymphoma</title><p>Burkitt&#8217;s lymphoma (BL) is highly aggressive and it is the most common pediatric cancer in the world (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B58" ref-type="bibr">58</xref>). Based on clinical observations and disease epidemiology, BL is classified into three different forms: endemic, sporadic and immunodeficiency-associated BLs (<xref rid="B79" ref-type="bibr">79</xref>). Endemic BL occurs in equatorial Africa and in Papua New Guinea, where essentially all cases are EBV genome-positive (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B80" ref-type="bibr">80</xref>). Sporadic BL has a wide global distribution, but has a much lower frequency with only 10&#8211;15% linked to EBV except for North East Brazil where the frequency of EBV in sporadic BL exceeds 80% (<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>). Immunodeficiency-associated BL has been diagnosed in HIV carriers who develop the lymphoma before progressing to AIDS, with an incidence of 10 to 100-fold higher than that of the sporadic BL, and about 30-40% of Immunodeficiency-associated BL are positive for EBV (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>).</p><p>BLs have a characteristic histology with sheets of monomorphic tumor cells resembling germinal centroblasts interspersed with macrophages, and have hypermutated Ig gene sequences typical of their geminal center (GC) origin and all carry chromosomal translocations that bring the c-myc gene under the control of either the Ig heavy chain or light chain loci (<xref rid="B84" ref-type="bibr">84</xref>). The resultant deregulation leading to constitutive expression of c-myc proteins at high levels in BL cells, and causes uncontrolled cell growth in BL (<xref rid="B85" ref-type="bibr">85</xref>). The expression of EBV genes in EBV positive BL is restricted to the type I latency program, where only EBNA-1 is expressed (<xref rid="B86" ref-type="bibr">86</xref>). Though the mechanism of EBV in the pathogenesis of BL is still unclear, it has been shown the expression of EBNA-1 in BL cell lines promotes cell proliferation by inhibiting apoptosis (<xref rid="B87" ref-type="bibr">87</xref>). Also, coinfection with other pathogens seem to play an important role, such as coinfection of EBV and Plasmodium falciparum in endemic BL, and coinfection of EBV and HIV in immunodeficiency-associated BLs (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B89" ref-type="bibr">89</xref>).</p></sec><sec id="s4_2"><title>Hodgkin Lymphoma</title><p>Hodgkin lymphoma (HL) originates from B cell and is characterized by the presence of few malignant multinucleated giant Reed Sternberg cells surrounded by a massively outnumbered non-neoplastic inflammatory infiltrate (<xref rid="B41" ref-type="bibr">41</xref>). Based on the nature of the infiltrate, classical HL is divided into four histologic subtypes namely the mixed cellularity (MC), nodular sclerosing (NS) and the rarer lymphocyte rich (LR) and lymphocyte-depleted (LD) subtypes (<xref rid="B60" ref-type="bibr">60</xref>). A minor, non-classical subtype of HL is referred to as lymphocyte predominant (LP). About 96% of MC cases are EBV genome-positive, whereas only 15-20% of cases of NS are associated with EBV. The rarer LR subtype is associated with EBV in 40% of cases, and most LD cases are EBV+ (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B90" ref-type="bibr">90</xref>). EBV is not associated with the non-classical LP subtype (<xref rid="B91" ref-type="bibr">91</xref>). Overall, about 30-40% of HL cases in North America and Europe were reported to be EBV positive, but in Latin America, Africa and Asia, EBV was found in almost 100% of all HL cases (<xref rid="B91" ref-type="bibr">91</xref>).</p><p>The Reed Sternberg cells in HL are B cells arrested at the germinal center (GC) or post-GC stages of B cell differentiation where somatic mutations in immunoglobulin (Ig) V genes are detected (<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B95" ref-type="bibr">95</xref>). The Reed Sternberg cells of the classical type of HL fail to express most B cell-specific genes, including Ig genes (<xref rid="B91" ref-type="bibr">91</xref>). Though the role of EBV in HL pathogenesis is still not fully understood, it is reported that all EBV-positive tumors consistently exhibit Latency II infection with high levels of the LMP1 and LMP2A proteins maintained in every Reed-Sternberg cell (<xref rid="B41" ref-type="bibr">41</xref>). LMP1 functions as a constitutively active variant of the CD40 receptor, and activates the aberrant transcriptional programs in Reed Sternberg cells, including the NF-&#954;B, JAK/STAT, AP-1, and (PI3K)/AKT pathways (<xref rid="B96" ref-type="bibr">96</xref>&#8211;<xref rid="B103" ref-type="bibr">103</xref>). LMP1 could also promote the survival of EBV-infected B cell receptor (BCR)-negative Reed Sternberg progenitors and increase the expression of anti-apoptotic molecules, including BCL2 and MCL1 (<xref rid="B104" ref-type="bibr">104</xref>&#8211;<xref rid="B106" ref-type="bibr">106</xref>). LMP2A mimics BCR, allows B cell development in the absence of BCR signaling, activates RAS/PI3K/AKT signaling and the mTOR pathway (<xref rid="B107" ref-type="bibr">107</xref>&#8211;<xref rid="B111" ref-type="bibr">111</xref>). LMP2A is also critical for the EBV-induced immortalization of BCR-negative GC B cells and LMP2A expression in different B cells systems can induce many of the cellular transcriptional changes characteristic of Reed Sternberg cells (<xref rid="B112" ref-type="bibr">112</xref>&#8211;<xref rid="B117" ref-type="bibr">117</xref>).</p></sec><sec id="s4_3"><title>Post-Transplant Lymphoproliferative Disorder</title><p>Post-transplant lymphoproliferative disorder (PTLD) is an uncontrolled B cell proliferation observed in some patients after solid organ or hematopoietic stem cell transplantation that can lead to non-Hodgkin and Hodgkin lymphoma (<xref rid="B118" ref-type="bibr">118</xref>). The prevalence of EBV-associated PTLD ranges from 1-20%, with incidence varying according to the type of allograft, age, and pretransplant EBV serostatus of transplant recipient (<xref rid="B42" ref-type="bibr">42</xref>). PTLD occurs as a result of increased proliferation of B cells due to either primary EBV infection, or reactivation of EBV from latently infected cells after treatment with immunosuppressant to avoid allograft rejection (<xref rid="B119" ref-type="bibr">119</xref>). The genome of EBV has been found in all of the B cells from PTLD patients. The use of immune suppressive drugs after organ transplant leads to depletion of EBV-specific T cells, and the impairment of EBV-specific T cell mediated immune surveillance results in uncontrolled lymphoproliferative blast, which causes PTLD in transplant recipients (<xref rid="B119" ref-type="bibr">119</xref>&#8211;<xref rid="B122" ref-type="bibr">122</xref>). PTLD display Latency III infection, and all the eight EBV latent antigens are expressed, including six EBV nuclear antigens EBNA 1, EBNA2, EBNA3A, EBNA3B, EBNA 3C, EBNA 6/LP and two latent membrane proteins LMP1 and LMP2 (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). These latent EBV proteins play key roles in the uncontrolled proliferation of B cells, and they are also the targets of EBV specific CD8+ T cells (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B123" ref-type="bibr">123</xref>).</p></sec><sec id="s4_4"><title>Nasopharyngeal Cancer</title><p>Nasopharyngeal cancer (NPC) is a squamous cell epithelial tumor that arises from the lateral wall of nasopharynx, including the fossa of Rosenm&#252;ller and superior posterior wall (<xref rid="B124" ref-type="bibr">124</xref>). NPC shows remarkable variation in ethnic and geographical distribution, with about 80% cases reported in Southern China and Southeast Asia (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B125" ref-type="bibr">125</xref>). NPC rates are low in the United States and Europe, the tumor occurs at intermediate to high incidence throughout South-East Asia and reaches its peak in populations of Southern Chinese decent where NPC is endemic, with a rate that is 30-fold higher than that of the United States and Europe (<xref rid="B126" ref-type="bibr">126</xref>). NPC is classified into two histological variants, namely squamous cell carcinomas (SCCs) and undifferentiated carcinomas of the nasopharyngeal type (UCNT) (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B127" ref-type="bibr">127</xref>). In a non-endemic region, about 63% of NPC cases are UCNT, while in Southern China, more than 95% of the cases are UCNT (<xref rid="B128" ref-type="bibr">128</xref>). Irrespective of geography and of incidence rate, all cases of undifferentiated NPC worldwide are EBV-associated, and the EBV genome present in every malignant cell (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Though genetic element and lifestyle/environmental factor contribute to NPC risk, EBV infection plays a critical role in NPC pathogenesis (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). The viral infection in NPC epithelial cells is clonal, developed from clonal proliferation of single EBV infected epithelial cell (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B129" ref-type="bibr">129</xref>). EBV viral gene expression in NPC tumor cells is an intermediate form, Latency I/II, all tumors express EBNA1, the non-coding EBERs and BART-miRs, and LMP2, whereas LMP-1 has been found in about two-thirds of NPC cases (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B130" ref-type="bibr">130</xref>). The BART-miRs and LMP2 promote epithelial cell growth (<xref rid="B131" ref-type="bibr">131</xref>&#8211;<xref rid="B134" ref-type="bibr">134</xref>). LMP1 activates the NFkB signaling pathway, which is a consistent feature of all NPCs (<xref rid="B135" ref-type="bibr">135</xref>).</p></sec><sec id="s4_5"><title>Gastric Cancer</title><p>Gastric cancer (GC) has a worldwide annual incidence of over 950,000 cases, and ranks as the third leading cause of cancer-related mortality globally (<xref rid="B42" ref-type="bibr">42</xref>). Though 75% of gastric cancers appear to be linked to H. pylori infection, up to 10% of gastric cancers are EBV-positive, accounting for 90,000 new cases each year (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). The EBV associated gastric cancers appear to form a clinically and pathogenetically distinct subgroup, occurs predominantly in the proximal stomach including the cardia, fundus and body, tend to present earlier in life, have a lower rate of lymph node involvement and a relatively favorable prognosis (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B136" ref-type="bibr">136</xref>&#8211;<xref rid="B138" ref-type="bibr">138</xref>). EBV associated gastric cancer is classified into three histological subtypes, lymphoepithelioma like carcinoma (LELC)-type, conventional adenocarcinoma (CA)-type, and carcinoma Crohn&#8217;s, and more than 90% of EBV associated gastric cancers show LELC-type morphology (<xref rid="B138" ref-type="bibr">138</xref>). Latency I or intermediate Latency I/II EBV infection are detected in EBV associated gastric cancer cells, and all the malignant cells within an individual tumor carry the same monoclonal virus genome (<xref rid="B139" ref-type="bibr">139</xref>). Though the role of EBV in the pathogenesis of gastric carcinoma is poorly understood, EBV-positive gastric cancer shows a distinctive hyper-methylated genome (<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>). It is proposed that EBV actively drives oncogenic change through epigenetic modification of the host cell genome, and silences tumor suppressor genes such as p16 and E cadherin (<xref rid="B142" ref-type="bibr">142</xref>).</p></sec></sec><sec id="s5"><title>EBV and Multiple Sclerosis</title><p>Multiple sclerosis (MS) is the most common autoimmune demyelinating disease, affecting both the brain and spinal cord. It is a lifetime, potentially debilitating condition with both remitting/relapsing and progressive phases. It typically occurs in young adults, especially Caucasians with a prevalence of 1/1,000 in this latter population and affects ~2.5 million people worldwide (<xref rid="B143" ref-type="bibr">143</xref>). EBV is recognized as the strongest infectious risk factor for this disease. Essentially all MS patients are EBV seropositive, and although still controversial, EBV may be a necessary pre-requisite for MS development (<xref rid="B144" ref-type="bibr">144</xref>). Several lines of evidence suggest an etiological role of EBV in MS, including but not limited to a high titer of anti-EBNA1 antibodies observed several years before MS onset, preliminary success of EBV-specific T cell therapy for treating progressive MS, and intriguing data from animal modeling (<xref rid="B145" ref-type="bibr">145</xref>&#8211;<xref rid="B148" ref-type="bibr">148</xref>). Of note, individuals carrying the HLA-DR15 gene (found in ~25% of the overall population) who develop IM have at least a 10-fold increased risk of developing MS (<xref rid="B149" ref-type="bibr">149</xref>). MS typically develops &gt;5 years after IM. Although a prophylactic EBV vaccine holds promise for markedly reducing the incidence of MS, confirmation will likely require long-term follow-up of individuals receiving the vaccine for other indications, most likely prevention of IM.</p></sec><sec id="s6"><title>Prophylactic EBV Vaccine</title><p>An EBV prophylactic vaccine holds great promise for prevention of cancers caused by EBV infection, as has been the case for prophylactic vaccines against human papilloma virus (HPV) and hepatitis B virus that cause ~600,000 and ~400,000 cases of new cancers each year respectively (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B150" ref-type="bibr">150</xref>). An EBV prophylactic vaccine would also be the most cost-effective approach for the management of infectious mononucleosis as well as EBV associated autoimmune disease such as MS (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). A prophylactic EBV vaccine uses the strategies to induce antibody response mainly neutralizing antibodies to block EBV infection of its target cells, whereas non-neutralizing antibodies as well as cell mediated immune response further improve prophylactic efficacy. The target cells of EBV are mainly B cells and epithelial cells, and EBV requires multiple envelope proteins for cell entry. EBV infection of B cells requires envelope proteins gp350, gH, gL, gB and gp42, whereas EBV infection of epithelial cells requires envelope proteins BMFR2, gH, gL and gB, therefore these envelope proteins could be excellent EBV prophylactic vaccine candidates [(<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B33" ref-type="bibr">33</xref>), <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>].</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Summary of prophylactic EBV vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Platform/Antigen/Adjuvant</th><th valign="top" align="center" rowspan="1" colspan="1">Animal/ Clinical trial</th><th valign="top" align="center" rowspan="1" colspan="1">Published year</th><th valign="top" align="center" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td valign="top" colspan="4" align="left" rowspan="1">
<bold>1. EBV envelope protein vaccines</bold>
</td></tr><tr><td valign="top" rowspan="3" align="left" colspan="1">Subunit vaccine, purified full length gp340 from virus, with liposome, Freund&#8217;s adjuvant, lipid A</td><td valign="top" align="left" rowspan="1" colspan="1">Mice,</td><td valign="top" rowspan="3" align="center" colspan="1">1984</td><td valign="top" rowspan="3" align="left" colspan="1">Antibody responses were induced (<xref rid="B70" ref-type="bibr">70</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cottontop</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">tamarins</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">Subunit vaccine, Purified full length gp340 from virus</td><td valign="top" align="left" rowspan="1" colspan="1">Cottontop</td><td valign="top" rowspan="2" align="center" colspan="1">1985</td><td valign="top" rowspan="2" align="left" colspan="1">Protection against malignant lymphoma (<xref rid="B151" ref-type="bibr">151</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">tamarins</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, purified gp350/gp220 from yeast and mammalian cells</td><td valign="top" align="left" rowspan="1" colspan="1">Rabbits</td><td valign="top" align="center" rowspan="1" colspan="1">1988</td><td valign="top" align="left" rowspan="1" colspan="1">EBV-specific neutralizing antibodies were induced (<xref rid="B152" ref-type="bibr">152</xref>).</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">Subunit vaccine, purified gp340, incorporated into immune-stimulating complexes</td><td valign="top" align="left" rowspan="1" colspan="1">Cottontop</td><td valign="top" rowspan="2" align="center" colspan="1">1988</td><td valign="top" rowspan="2" align="left" colspan="1">Protection against malignant lymphoma (<xref rid="B153" ref-type="bibr">153</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">tamarins</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">Subunit vaccine, recombinant gp340 adjuvanted with Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Cottontop</td><td valign="top" rowspan="2" align="center" colspan="1">1994</td><td valign="top" rowspan="2" align="left" colspan="1">Protection of 3/5 cottontop tamarins against malignant lymphoma (<xref rid="B154" ref-type="bibr">154</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">tamarins</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, recombinant single chain gp350 with Freund&#8217;s adjuvant versus Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Rabbits</td><td valign="top" align="center" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">High titers of neutralizing antibody elicited (<xref rid="B155" ref-type="bibr">155</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, recombinant single chain gp350 with AS04 versus alum</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II</td><td valign="top" align="center" rowspan="1" colspan="1">2007</td><td valign="top" align="left" rowspan="1" colspan="1">Induced neutralizing antibodies in 70% of human subjects, and decreased IM by 78% (<xref rid="B156" ref-type="bibr">156</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, recombinant tetrameric versus monomeric gp350<sup>1-470</sup> adjuvanted with alum/CpG-ODN</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="center" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Tetrameric gp350 induced &#8764;20- fold higher titers of IgG and &gt;19-fold higher neutralizing titers at the highest dose (<xref rid="B157" ref-type="bibr">157</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, self- assembling nanoparticles expressing gp350<sup>1-123</sup>
</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="center" rowspan="1" colspan="1">2015</td><td valign="top" align="left" rowspan="1" colspan="1">gp350-nanoparticle elicited 10- to 100-fold higher neutralizing titers compared to soluble gp350 (<xref rid="B158" ref-type="bibr">158</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, recombinant monomeric gH/gL, trimeric gH/gL and trimeric gB, adjuvanted with alum/CpG-ODN</td><td valign="top" align="left" rowspan="1" colspan="1">Rabbits</td><td valign="top" align="center" rowspan="1" colspan="1">2016</td><td valign="top" align="left" rowspan="1" colspan="1">Trimeric and monomeric gH/gL, trimeric gB, and tetrameric gp350 induced EBV-neutralizing titers &gt;100-, 20-, 18-, and 4-fold higher, respectively, than monomeric gp350 (<xref rid="B159" ref-type="bibr">159</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, Fc-fused gp350 dimer with Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="center" rowspan="1" colspan="1">2018</td><td valign="top" align="left" rowspan="1" colspan="1">Elicited significantly higher neutralizing titers than gp350 monomer (<xref rid="B160" ref-type="bibr">160</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, self-assembling nanoparticles expressing gH/gL or gH/gL/gp42 with SAS adjuvant</td><td valign="top" align="left" rowspan="1" colspan="1">Mice, cynomolgus macaques</td><td valign="top" align="center" rowspan="1" colspan="1">2019</td><td valign="top" align="left" rowspan="1" colspan="1">gH/gL and gH/gL/gp42-ferritin nanoparticles elicited &gt;40- and ~4-fold higher neutralization titers for B cells in monkeys compared with soluble proteins; for epithelial cells, &gt;25- and ~4-fold higher neutralizing titers were elicited. (<xref rid="B161" ref-type="bibr">161</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine, recombinant trimeric gB, monomeric gH/gL and their combination, adjuvanted with alum/CpG-ODN</td><td valign="top" align="left" rowspan="1" colspan="1">Rabbits, humanized mice</td><td valign="top" align="center" rowspan="1" colspan="1">2021</td><td valign="top" align="left" rowspan="1" colspan="1">Sera from rabbits immunized trimeric gB or monomeric gH/gL protected humanized mice from lethal dose EBV challenge and markedly decreased EBV loads. Immunization with the combination of gB and gH/gL elicited strong synergistic neutralizing activity (<xref rid="B162" ref-type="bibr">162</xref>).</td></tr><tr><td valign="top" colspan="4" align="left" rowspan="1">
<bold>2. EBV Virus-Like particle (VLP) vaccines</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EBV-derived VLP, produced via the deletion of the EBV terminal repeats, EBNA2, EBNA 3A, 3B and 3C, LMP1 and BZLF1</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="center" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">EBV-specific humoral and cellular immune responses were induced (<xref rid="B163" ref-type="bibr">163</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EBV-derived VLP, produced by fusing EBNA1 and EBNA3C to the major tegument protein BNRF1</td><td valign="top" align="left" rowspan="1" colspan="1">Humanized mice</td><td valign="top" align="center" rowspan="1" colspan="1">2018</td><td valign="top" align="left" rowspan="1" colspan="1">Potent CD4+ T cell responses elicited, and EBV loads were reduced (<xref rid="B164" ref-type="bibr">164</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Newcastle disease virus (NDV) VLP, expressing gp350/220 Ectodomain</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="center" rowspan="1" colspan="1">2015</td><td valign="top" align="left" rowspan="1" colspan="1">Elicited neutralizing antibody responses, but not higher than that of soluble gp350/220 (<xref rid="B165" ref-type="bibr">165</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDV VLP, expressing gH/gL-EBNA1 or gB-LMP2</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="center" rowspan="1" colspan="1">2017</td><td valign="top" align="left" rowspan="1" colspan="1">Elicited EBV-specific T-cell responses and higher EBV neutralizing titers (<xref rid="B166" ref-type="bibr">166</xref>).</td></tr><tr><td valign="top" colspan="4" align="left" rowspan="1">
<bold>3. Synthesized mRNA EBV vaccines</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Synthesized mRNA encoding gp350, gB, gH/gL and gp42</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="center" rowspan="1" colspan="1">2021</td><td valign="top" align="left" rowspan="1" colspan="1">Elicited ~20- and ~100-fold higher neutralizing activities for B cells and epithelial cells respectively compared to human sera.</td></tr></tbody></table></table-wrap><sec id="s6_1"><title>Recombinant EBV Envelope Protein Vaccines</title><p>Early efforts in EBV vaccine development were focused on gp350 (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). EBV gp350 is the most abundant EBV envelope protein, and about half of the EBV neutralizing activity in EBV seropositive human sera is against gp350 (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B161" ref-type="bibr">161</xref>). Purified or recombinant gp350 was shown to protect cotton top tamarins from lymphoma caused by EBV infection, and similar results were reported with adenovirus or vaccinia virus expressing gp350 (<xref rid="B69" ref-type="bibr">69</xref>&#8211;<xref rid="B76" ref-type="bibr">76</xref>). Phase I and II studies of a recombinant gp350 produced in Chinese hamster ovary cells showed that the recombinant gp350 induced neutralizing antibodies in humans in 70% of the subjects, and reduced the rate of infectious mononucleosis by 78% in the vaccinated subjects but did not prevent EBV infection (<xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B167" ref-type="bibr">167</xref>). This is most likely because gp350 is not strictly essential for EBV virus infection of B cells but only important for efficient infection, as well as the inability of gp350 induced antibodies to protect against EBV infection of epithelial cells (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B168" ref-type="bibr">168</xref>).</p><p>Our group was the first to report in 2016 that recombinant EBV gH/gL and gB proteins induced markedly higher EBV neutralizing antibodies compared to gp350, where a trimeric form of gH/gL and a tetrameric form of gp350 elicited significantly higher EBV neutralizing activities compared to their monomeric counterparts (<xref rid="B159" ref-type="bibr">159</xref>). This was confirmed by the recently published study by Bu et&#160;al. that EBV gH/gL or gH/gL/gp42 nanoparticles induced potent neutralizing antibody responses in mice and non-human primates, which blocked EBV-target cell fusion and prevented EBV infection of B cells and epithelial cells (<xref rid="B161" ref-type="bibr">161</xref>). Though these nanoparticle EBV vaccine candidates induced 10- to 1000-fold higher titers of neutralizing antibodies compared to that of soluble proteins, as the gH, gL and/or gp42 proteins were highly packed into the nanoparticles, the expression of native conformational epitopes of these EBV envelope proteins could be prevented (<xref rid="B161" ref-type="bibr">161</xref>). It was reported that virus like particles and nanoparticles could induce quantitatively high antibody responses whereas recombinant proteins expressing native epitopes could elicit antibody responses that are high both quantitatively and qualitatively (<xref rid="B169" ref-type="bibr">169</xref>&#8211;<xref rid="B172" ref-type="bibr">172</xref>). This has been confirmed with the herpes virus recombinant envelope protein vaccine candidates produced in our laboratory including EBV gH/gL and EBV trimeric gB (<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B174" ref-type="bibr">174</xref>).</p><p>EBV gH/gL and gB constitute the core fusion machinery, which play the critical roles for EBV fusion and entry into all target cells, thus making the inclusion of EBV gH/gL and gB more promising as prophylactic EBV vaccine candidates than the use of gp350 alone (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>). As EBV gH/gL and gB could both elicit neutralizing antibodies, the presence of gH/gL neutralizing antibodies and gB neutralizing antibodies simultaneously would most likely exhibit synergistic effects (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B33" ref-type="bibr">33</xref>). In this regard, we recently demonstrated that mixing EBV gH/gL anti-sera with EBV gB anti-sera resulted in strong synergistic neutralizing activity for both B cells and epithelial cells. This may have been due to the ability of gH/gL and gB antibodies to block different steps in EBV infection of target cells (<xref rid="B162" ref-type="bibr">162</xref>). Immunization with the combination of EBV gH/gL and trimeric gB also elicited markedly higher EBV neutralizing activities for both B cells and epithelial cells as compared to that induced by immunization with EBV gH/gL or trimeric gB alone, demonstrating strong synergistic effects of EBV core fusion envelope proteins in elicitation of neutralizing antibodies (<xref rid="B162" ref-type="bibr">162</xref>). The strong synergistic effects are most likely due to the sequential coordination of these envelope proteins in mediating EBV entry and infection of target cells, suggesting that the combination of EBV core fusion machinery envelope proteins gH/gL and trimeric gB could be a highly effective EBV prophylactic vaccine. Recombinant gp350 also demonstrated synergistic EBV neutralizing activities when used with EBV gH/gL and/or gB (<xref rid="B175" ref-type="bibr">175</xref>). Further, we recently reported that the immune sera from rabbits immunized with EBV gH/gL or trimeric gB protected humanized mice from death after lethal dose EBV challenge and markedly decreased the EBV in peripheral blood (<xref rid="B162" ref-type="bibr">162</xref>). Collectively, these data strongly suggest that the combination of EBV gH/gL, gB and gp350 could be an ideal EBV prophylactic vaccine that can elicit markedly high synergistic EBV neutralizing activity with the potential to induce sterilizing immunity. EBV gp350, gH, gL, and gB can also induce CD4+ and CD8+ T cell immune responses, and have demonstrated to inhibit proliferation of EBV-infected primary B cells <italic toggle="yes">in vitro</italic> before latency was established (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B176" ref-type="bibr">176</xref>, <xref rid="B177" ref-type="bibr">177</xref>). The T cell immune responses induced by EBV gp350, gH, gL, and gB could further increase the efficacy of a prophylactic vaccine by promoting the killing of recently infected epithelial cells and B cells and stopping B-cell transformation if the EBV is not blocked by neutralizing antibodies.</p></sec><sec id="s6_2"><title>Virus-Like Particle EBV Vaccines</title><p>Virus-Like particle (VLP) vaccines have been successfully developed for hepatitis B virus and human papilloma virus, but the development of VLP vaccines for EBV has met challenges. The first successful EBV VLPs were created by the deletion of the EBV terminal repeats, and potential oncogenes namely EBNA2, 3A, 3B and 3C, LMP1 and BZLF1 (<xref rid="B163" ref-type="bibr">163</xref>). These EBV VLPs were shown to elicit EBV-specific humoral and cellular immune responses after immunization in mice (<xref rid="B163" ref-type="bibr">163</xref>). Later, the viral packaging and nuclear egress proteins BFLF1/BFRF1A were further deleted to improve safety, and the EBV VLPs produced could induce comparable CD4+ T cell responses as that of wildtype EBV, but the responses against structural proteins were reduced. More immunogenic EBV VLPs were made by fusing latent antigens EBNA1 and EBNA3C to the major tegument protein BNRF1 of EBV. The EBV VLPs produced were able to stimulate potent CD4+ T cell responses against structural as well as latent EBV protein epitopes, and reduced EBV loads in the peripheral blood of humanized mice after immunization (<xref rid="B164" ref-type="bibr">164</xref>). However, the possibility of repacking of EBV DNA remains a safety concern for the EBV-derived VLPs. Another approach used a novel Newcastle disease virus (NDV) VLP platform displaying the EBV gp350/220 ectodomain, but the EBV neutralizing titers elicited in mice were not significantly higher than that induced by soluble gp350/220 (<xref rid="B165" ref-type="bibr">165</xref>). The NDV VLP platform was subsequently used to produce gH/gL-EBNA1 VLPs and gB/LMP2 VLPs. Both elicited higher EBV neutralizing titers in mice, but not comparable to that elicited by UV-inactivated EBV, suggesting potency concerns with the NDV VLP EBV vaccines (<xref rid="B166" ref-type="bibr">166</xref>).</p></sec><sec id="s6_3"><title>Synthesized mRNA EBV Vaccines</title><p>The rapid and successful development of synthesized mRNA vaccines against SARS-CoV2 for the COVID-19 pandemic has encouraged the development of synthesized mRNA EBV vaccines (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>). After demonstrating its mRNA vaccine candidate encoding gp350, gB, gH/gL and gp42 induced significantly higher EBV neutralizing titers in mice compared to human sera, Moderna has initiated phase I clinical trial of its mRNA EBV vaccine. However, there are potential challenges with this approach. First, whether mRNA vaccines could induce long-term memory responses in humans remains to be determined, and may require repeated booster immunizations to maintain high titers of neutralizing antibodies and potent T cell immune responses. This would be unacceptable for pathogens such as EBV that rarely cause a medical emergency. Second, mRNA is an intrinsic adjuvant that may limit multi-component formulations because of unacceptable side effects. Currently it has been reported that mRNA vaccines against SARS-CoV2 may have caused myocarditis and pericarditis in a small number of subjects. Long-term adverse effects as well as adverse effects after multiple repeated immunizations are still unknown.</p></sec><sec id="s6_4"><title>Viral Vector EBV Vaccines</title><p>The viral vector vaccine platform has mainly been used for the development of therapeutic EBV vaccines, which are discussed in detail later in the therapeutic EBV vaccine section.</p></sec></sec><sec id="s7"><title>Therapeutic EBV Vaccine</title><p>The immune system plays a critical role in the control of tumors, and the immune-based tumor-specific therapeutic approaches could be highly effective with limited adverse effects (<xref rid="B21" ref-type="bibr">21</xref>). Therapeutic EBV vaccines aim at boosting the existing or inducing novel antiviral adaptive immune responses in patients with EBV-associated cancers (<xref rid="B21" ref-type="bibr">21</xref>). The targets of EBV therapeutic vaccines are focused on EBNA1, LMP2 and/or LMP1, as these proteins are involved in the modulation of key factors that contribute to the transformation of normal cells into tumors [(<xref rid="B180" ref-type="bibr">180</xref>&#8211;<xref rid="B185" ref-type="bibr">185</xref>), <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>]. Most therapeutic EBV vaccination approaches have focused on patients with NPC, and early clinical trials were done with dendritic cells (DCs)-based EBV vaccines (<xref rid="B21" ref-type="bibr">21</xref>). Autologous monocyte-derived dendritic cells (DCs) from NPC patients pulsed with HLA-A11-, -A24-, or -B4-restricted LMP2 epitopes boosted EBV-specific CD8+ T-cell responses in nine of 16 patients, and induced partial tumor regression in two patients (<xref rid="B191" ref-type="bibr">191</xref>). In another phase I clinical trial where 16 HLA-A2+ NPC patients were vaccinated with autologous DCs pulsed with HLA-A2-restricted LMP2A peptides, the LMP2-specific T-cell response was improved in 9 of 16 patients, which correlated with a modest decrease in serum EBV DNA levels (<xref rid="B187" ref-type="bibr">187</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Summary of therapeutic EBV vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Platform/Antigen</th><th valign="top" align="center" rowspan="1" colspan="1">Disease</th><th valign="top" align="center" rowspan="1" colspan="1">Clinical trial</th><th valign="top" align="center" rowspan="1" colspan="1">Published year</th><th valign="top" align="center" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td valign="top" colspan="5" align="left" rowspan="1">
<bold>1. Dendritic cells (DCs)-based EBV vaccines</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous monocyte-derived DCs pulsed with LMP2 peptides</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="left" rowspan="1" colspan="1">Phase I</td><td valign="top" align="center" rowspan="1" colspan="1">2002</td><td valign="top" align="left" rowspan="1" colspan="1">EBV-specific CD8+ T-cell responses boosted in 9/16 patients, and partial tumor regression induced in 2/16 patients (<xref rid="B186" ref-type="bibr">186</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous DCs pulsed with LMP2A peptides</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="left" rowspan="1" colspan="1">Phase I</td><td valign="top" align="center" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">LMP2-specific T-cell response improved in 9/16 patients, with decreased serum EBV load (<xref rid="B187" ref-type="bibr">187</xref>).</td></tr><tr><td valign="top" colspan="5" align="left" rowspan="1">
<bold>2. Recombinant viral vector vaccines</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adenoviral vector expressing LMP2</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="left" rowspan="1" colspan="1">Phase I</td><td valign="top" align="center" rowspan="1" colspan="1">2016</td><td valign="top" align="left" rowspan="1" colspan="1">LMP2-specific CD3+ CD4+ cells increased (<xref rid="B188" ref-type="bibr">188</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Modified vaccinia ankara (MVA) expressing EBNA1 and LMP2 as a fusion protein (MVA-EL)</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="left" rowspan="1" colspan="1">Phase I</td><td valign="top" align="center" rowspan="1" colspan="1">2013</td><td valign="top" align="left" rowspan="1" colspan="1">Two-fold increase in the T-cell response to EBNA1 and/or LMP2 in 15/18 patients treated (<xref rid="B189" ref-type="bibr">189</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MVA-EL</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="left" rowspan="1" colspan="1">Phase I</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Increased numbers and differentiationof CD4+ and CD8+ T-cells to EBNA1 and LMP2 in 4/8 patients (<xref rid="B190" ref-type="bibr">190</xref>).</td></tr></tbody></table></table-wrap><p>Recombinant viral vector vaccines were later developed to present a wide range of epitopes to improve efficacy. One of the approaches used a recombinant adenoviral vector to deliver LMP2 antigen, and demonstrated a dose dependent increase in the proportion of LMP2-specific CD3+ CD4+ cells in the peripheral blood of immunized NPC patients in a clinical trial (<xref rid="B188" ref-type="bibr">188</xref>). A modified vaccinia ankara (MVA) expressing the carboxyl terminus of EBNA1 and full-length LMP2 as a fusion protein (MVA-EL) was shown to efficiently expand the EBNA1- and LMP2-specific CD4+ and CD8+ T cells from the peripheral blood lymphocytes of seropositive healthy donors <italic toggle="yes">in vitro</italic> (<xref rid="B192" ref-type="bibr">192</xref>). A phase I clinical trial of the MVA-EL vaccine carried out in Hong Kong where NPC patients in remission received three intradermal MVA-EL immunizations at 3-weekly intervals, and demonstrated a two-fold increase in the T-cell response to one or both vaccine antigens in 15 of 18 treated patients (<xref rid="B189" ref-type="bibr">189</xref>). Further, these T-cell responses were mapped to known CD4+ and CD8+ T-cell epitopes of EBNA1 and/or LMP2 (<xref rid="B189" ref-type="bibr">189</xref>). A second phase I clinical trial of the MVA-EL vaccine conducted in UK showed an increase in CD4+ and CD8+ T-cell responses to one or both of the antigens in 8 of the 14 NPC patients tested, as well as increased differentiation and functional diversification in the EBNA1- and LMP2-specific CD4+ and CD8+ cells (<xref rid="B190" ref-type="bibr">190</xref>).</p><p>Though the EBV therapeutic vaccine clinical trials have shown many potential clinical benefits, further remains to be done. The DC vaccines can only deliver limited antigen epitopes and are expensive to prepare (<xref rid="B21" ref-type="bibr">21</xref>). Recombinant viral vector vaccines can deliver a wide range of epitopes, but the anti-viral vector immune responses elicited after repeated immunizations are a big obstacle, which could markedly decrease the efficacy of viral vector vaccines. Different vaccine platforms should be explored for the development of EBV therapeutic vaccines. Although T-cell responses were believed to be critical in controlling EBV-associated cancers, high levels of neutralizing antibodies are associated with a lower risk of NPC, and NPC progression has been shown to correlate with active EBV replication and high titers of EBV in the peripheral blood, thus a vaccine inducing potent EBV neutralizing antibodies may reduce the risk of EBV-related cancers (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B193" ref-type="bibr">193</xref>). The role of the neutralizing antibody response in EBV-associated malignancies needs to be explored further. A vaccine platform delivering EBNA1, LMP1/LMP2, gp350, gH/gL and gB simultaneously may significantly increase the efficacy of a therapeutic vaccine against EBV associated cancers.</p></sec><sec id="s8"><title>Immunotherapy Against EBV Associated Cancer</title><sec id="s8_1"><title>Adoptive T-Cell Therapy</title><p>Adoptive T-cell therapy (ACT) has been successfully used for the treatment of PTLD, and the reconstitution of cellular immunity provides a powerful mechanism to control EBV-associated PTLD [(<xref rid="B21" ref-type="bibr">21</xref>), <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>]. The first ACT clinical trial demonstrated that infusion of donor-derived EBV-specific T lymphocytes into allogeneic hematopoietic stem cell transplantation (HSCT) patients with donor-derived EBV-associated immunoblastic lymphoma induced a complete regression in 5/5 patients, but graft-versus-host disease (GvHD) was developed due to the alloreactive T cells (<xref rid="B194" ref-type="bibr">194</xref>). Later EBV-specific cytotoxic T lymphocytes (CTLs) were obtained by <italic toggle="yes">in vitro</italic> stimulation with EBV-transformed B lymphoblastoid cell lines (LCLs), synthetic peptides or recombinant viral vectors, and followed by selection with TCR tetramer binding or IFN-&#947; capture. Clinical trials demonstrated that these <italic toggle="yes">in vitro</italic>-expanded donor-derived EBV-specific CTLs could be used effectively for the prevention and treatment of PTLD in HSCT patients with minimal alloreactivity (<xref rid="B64" ref-type="bibr">64</xref>&#8211;<xref rid="B66" ref-type="bibr">66</xref>). Similar strategies were also used to expand <italic toggle="yes">in vitro</italic> the autologous EBV-specific CTLs from highly immunosuppressed solid organ transplantation (SOT) patients and successfully controlled EBV-associated PTLD (<xref rid="B195" ref-type="bibr">195</xref>&#8211;<xref rid="B197" ref-type="bibr">197</xref>). Encouraged by the excellent results of treatment of PTLD with ACT, ACTs have been developed for NPC and HL using <italic toggle="yes">in vitro</italic> expanded CTLs targeting type II latency antigens EBNA1, LMP1 and LMP2 [(<xref rid="B198" ref-type="bibr">198</xref>, <xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B206" ref-type="bibr">206</xref>&#8211;<xref rid="B208" ref-type="bibr">208</xref>), <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>]. Clinical trials with these expanded CTLs significantly increased response rates as well as overall survival in both NPC and HL patients (<xref rid="B186" ref-type="bibr">186</xref>, <xref rid="B200" ref-type="bibr">200</xref>, <xref rid="B201" ref-type="bibr">201</xref>).</p></sec><sec id="s8_2"><title>EBV Specific T Cell Receptor Engineered T Cell Therapy</title><p>T cell receptor (TCR) engineered T cell therapy is a promising approach to cancer treatment, and has been used in the treatment of HPV associated cancer targeting E7 antigen with impressive results (<xref rid="B209" ref-type="bibr">209</xref>&#8211;<xref rid="B211" ref-type="bibr">211</xref>). TCRs that recognize EBNA3A, EBNA3B, LMP1, LMP2, BRLF1 and BMLF1 have been generated from specific CD8+ T cell clones, and tested their effectiveness in eliminating EBV transformed B cells (<xref rid="B212" ref-type="bibr">212</xref>&#8211;<xref rid="B214" ref-type="bibr">214</xref>). It was reported that the T cells transduced with these T cell receptors recognized autologous LCLs weakly, partially due to limited latent EBV antigen expression in LCLs. However, the tumor progression of a NPC cell line expressing LMP2 implanted into nude mice was significantly attenuated by LMP2 TCR transduced T cells (<xref rid="B215" ref-type="bibr">215</xref>). It was hypothesized that some of the transduced TCR &#945; and &#946; chains might pair with the endogenous TCR &#946; and &#945; chains of the T cells, which reduce the number of transduced TCR and thereby prevented efficient LCL recognition (<xref rid="B216" ref-type="bibr">216</xref>). To improve correct pairing of transduced TCR &#945; and &#946; chains, chimeric TCRs were generated, where the variable domains of TCR &#945; and &#946; chains from EBV specific T cell clones were fused to the corresponding mouse TCR constant regions (<xref rid="B217" ref-type="bibr">217</xref>). The stability of chimeric TCRs was further improved by introducing an additional disulfide bond between the &#945; and &#946; chain of the murine TCR constant regions (<xref rid="B202" ref-type="bibr">202</xref>, <xref rid="B218" ref-type="bibr">218</xref>). As a result, T cells transduced with a chimeric TCR recognizing LMP2 were able to kill up to half of co-incubated LMP2 positive cells <italic toggle="yes">in vitro</italic> and to suppress LMP2 expressing tumor cell growth in immune compromised mice [(<xref rid="B202" ref-type="bibr">202</xref>), <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>]. Similar results were observed with a TCR recognizing EBV LMP1, and T cells transduced with LMP1 specific TCR doubled the survival of immune compromised mice challenged with LMP1 expressing tumor cells (<xref rid="B203" ref-type="bibr">203</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>Summary of EBV immune cell therapies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Platform</th><th valign="top" colspan="2" align="center" rowspan="1">Disease, clinical trial/Animal model</th><th valign="top" align="center" rowspan="1" colspan="1">Published year</th><th valign="top" align="center" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td valign="top" colspan="5" align="left" rowspan="1">
<bold>1. Adoptive T-cell therapy</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Donor-derived EBV-specific T lymphocytes</td><td valign="top" align="left" rowspan="1" colspan="1">PTLD</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">1994</td><td valign="top" align="left" rowspan="1" colspan="1">Complete regression in 5/5 patients, but graft-versus-host disease developed (<xref rid="B194" ref-type="bibr">194</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EBV-specific cytotoxic T-lymphocyte (CTL) lines from donor</td><td valign="top" align="left" rowspan="1" colspan="1">PTLD, HSCT</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">1995</td><td valign="top" align="left" rowspan="1" colspan="1">Complete regression of immunoblastic lymphoma in 1/1 patients, EBV reactivation controlled in 3/3 patients without lymphoma (<xref rid="B64" ref-type="bibr">64</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Donor-derived polyclonal CD4+ and CD8+ T-cell lines</td><td valign="top" align="left" rowspan="1" colspan="1">PTLD, HSCT</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">1998</td><td valign="top" align="left" rowspan="1" colspan="1">Complete regression of immunoblastic lymphoma in 2/2 patients, EBV reactivation controlled in 6/6 patients without lymphoma (<xref rid="B65" ref-type="bibr">65</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous EBV-specific CTL lines</td><td valign="top" align="left" rowspan="1" colspan="1">PTLD, SOT</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Significant regression of the PTLD in 1/1 patient (<xref rid="B195" ref-type="bibr">195</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous EBV-specific CD8 and CD4 lymphocytes</td><td valign="top" align="left" rowspan="1" colspan="1">PTLD, SOT</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Complete regression of liver PTLD in 1/1 patient, prevention of PTLD in 12/12 patients (<xref rid="B196" ref-type="bibr">196</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous EBV-specificcytotoxic T lymphocytes</td><td valign="top" align="left" rowspan="1" colspan="1">SOT</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">2002</td><td valign="top" align="left" rowspan="1" colspan="1">Decrease EBV load, prevention of PTLD in 7/7 patients (<xref rid="B197" ref-type="bibr">197</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous EBV-specific cytotoxic T lymphocytes</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Complete response in 4/10 patients and partial response in 2/10 patients (<xref rid="B198" ref-type="bibr">198</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous EBV-specific cytotoxic T lymphocytes</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="center" rowspan="1" colspan="1">I/II</td><td valign="top" align="center" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Complete response in 7/15 patients and partial response in 3/15 patients (<xref rid="B199" ref-type="bibr">199</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous EBV-specific cytotoxic T lymphocytes</td><td valign="top" align="left" rowspan="1" colspan="1">NPC</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="center" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">Complete response in 3/35 patients and partial response 22/35 patients (<xref rid="B200" ref-type="bibr">200</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous EBV-specific cytotoxic T lymphocytes targeting LMP2</td><td valign="top" align="left" rowspan="1" colspan="1">Lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="center" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">Complete response in 11/21 patients and partial response 2/21 patients (<xref rid="B201" ref-type="bibr">201</xref>).</td></tr><tr><td valign="top" colspan="5" align="left" rowspan="1">
<bold>2. EBV Specific T Cell Receptor (TCR) engineered T cell therapy</bold>
</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">Autologous CD8 and CD4 Lymphocytes expressing LMP2 specific TCR</td><td valign="top" colspan="2" align="center" rowspan="1">NSG mouse</td><td valign="top" rowspan="2" align="center" colspan="1">2015</td><td valign="top" rowspan="2" align="left" colspan="1">Lysed LMP2+ NPC cells and inhibited tumor growth in a mouse model (<xref rid="B202" ref-type="bibr">202</xref>).</td></tr><tr><td valign="top" colspan="2" align="center" rowspan="1">NPC model</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Autologous CD8 and CD4 Lymphocytes expressing LMP1 specific TCR</td><td valign="top" colspan="2" align="center" rowspan="1">NSG mouse tumor model</td><td valign="top" align="center" rowspan="1" colspan="1">2018</td><td valign="top" align="left" rowspan="1" colspan="1">Doubled the survival time of mice bearing tumor (<xref rid="B203" ref-type="bibr">203</xref>).</td></tr><tr><td valign="top" colspan="5" align="left" rowspan="1">
<bold>3. EBV Specific Chimeric Antigen Receptor (CAR) T cell therapy</bold>
</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">CD8 and CD4 Lymphocytes Expressing LMP1 specific CAR</td><td valign="top" colspan="2" align="left" rowspan="1">NSG mouse</td><td valign="top" align="center" rowspan="1" colspan="1">2014</td><td valign="top" rowspan="2" align="left" colspan="1">Killed 70% of LMP1 overexpressing NPC cells in vitro, and significantly reduced the growth of NPC tumor overexpressing LMP1 (<xref rid="B204" ref-type="bibr">204</xref>, <xref rid="B205" ref-type="bibr">205</xref>).</td></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">tumor model</td><td valign="top" align="center" rowspan="1" colspan="1">2019</td></tr></tbody></table></table-wrap></sec><sec id="s8_3"><title>EBV Specific Chimeric Antigen Receptor T Cell Therapy</title><p>T cells expressing chimeric antigen receptors (CARs) targeting CD19, CD20, CD22 and CD30 were able to kill around 50% of different B cell lymphomas in cell culture, and have provided spectacular results in clinical trials, with 60% of B cell lymphoma and leukemia patients in complete remission after treatment (<xref rid="B219" ref-type="bibr">219</xref>&#8211;<xref rid="B223" ref-type="bibr">223</xref>). However, significant adverse effects of cytokine release syndrome and neurotoxicity have also been observed due to the abundance of target cells, including both normal and malignant B cells after infusion of CAR-T cells (<xref rid="B123" ref-type="bibr">123</xref>). Further, deficiencies in humoral immune responses could be induced due to the persistent non-specific killing of B cells and predispose the patients for respiratory and gastrointestinal infections (<xref rid="B224" ref-type="bibr">224</xref>). To avoid the adverse effects of B cell antigen specific CAR-Ts, EBV specific CAR-Ts have been explored for treatment of NPC. LMP1 specific CAR-T cells could kill up to 70% of LMP1 overexpressing NPC cells <italic toggle="yes">in vitro</italic>, and intratumoral injection of anti-LMP1 CAR-T cells significantly reduced the growth of NPC tumor overexpressing LMP1 in immune compromised mice [(<xref rid="B204" ref-type="bibr">204</xref>, <xref rid="B205" ref-type="bibr">205</xref>), <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>]. Though it is questionable whether the LMP1 specific CAR-T cells could target the tumor cells in NPC patients where LMP1 expression is usually much lower, the results are encouraging. Clinical trials using LMP1 specific CAR-T cells for the treatment of NPC are underway, but no results have yet reported. EBV LMP2 is another promising target for treatment of EBV associated cancers.</p></sec></sec><sec id="s9"><title>Conclusion</title><p>EBV infects more than 95% of the human population, causes IM in 70% of adolescents and young adults in developed countries, accounts for 1.5% of all cancers worldwide and represent 1.8% of all cancer deaths. An EBV prophylactic vaccine holds great promise for prevention of EBV associated cancers such as BL, HL, PTLD, NPC, and GC, and would also be the most cost-effective approach for the management of IM as well as EBV associated autoimmune disease such as MS. Though VLP, viral vector and mRNA platforms have been used for the development of an EBV prophylactic vaccine, the approach using recombinant EBV envelope proteins has made advancement the most. EBV envelope proteins including gH/gL, gB, gp350 play key roles in EBV entry and infection of its target cells, and neutralizing antibodies elicited by each of these proteins have shown to prevent EBV infection of target cells, markedly decrease EBV titers in the blood of humanized mice, and prevent their death after challenge with lethal dose EBV. Recent studies demonstrated that immunization with the combination of recombinant EBV gH/gL and gB proteins markedly increased the EBV neutralizing activity compared to immunization with individual protein. These data suggest that the combination of EBV gH/gL, gB and gp350 could be an ideal EBV prophylactic vaccine that can elicit markedly high EBV neutralizing activity with the potential to induce sterilizing immunization, prevent primary EBV infection and therefore prevent EBV associated cancers as well IM and MS.</p><p>For patients with EBV-associated cancers, therapeutic EBV vaccines targeting latent proteins EBNA1, LMP2 and/or LMP1 are promising treatments. Though the current DC-based and viral vector EBV therapeutic vaccines have shown significant limitations, different vaccine platforms targeting both latent and lytic envelope proteins including EBNA1, LMP1/LMP2, gp350, gH/gL and gB simultaneously can be explored to improve efficacy. Immune cell therapies for EBV-associated cancers have emerged as another highly promising treatment. ACT has demonstrated to cure and prevent PTLD, and has shown to be highly effective in the treatment of NPC and HL by targeting latent proteins EBNA1, LMP1/LMP2. To further improve efficacy and minimize adverse effects, EBV specific CAR-T and TCR engineered T cell therapies targeting EBV latent protein LMP1, LMP2 and/or EBNA1 have been developed, with the goal of specific killing of EBV+ cancer cells highly efficiently.</p></sec><sec sec-type="author-contributions" id="s10"><title>Author Contributions</title><p>XC prepared the manuscript draft, CMS provided comments to the text and figures, read and approved the final manuscript. All&#160;authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="funding-information" id="s11"><title>Funding</title><p>This research was supported in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. This research was also supported by the Dean&#8217;s Research and Education Endowment Fund from Uniformed Services University of the Health Sciences (USUHS). USUHS had no involvement in design of study, data analysis or interpretation, nor manuscript preparation or study publication.</p></sec><sec id="s12"><title>Author Disclaimer</title><p>The opinions expressed herein are those of the authors and are not necessarily representative of those of USUHS, the United States Army, Navy or Air Force, or the Department of Defense (DOD). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p></sec><sec sec-type="COI-statement" id="s13"><title>Conflict of Interest</title><p>CMS was employed by Citranvi Biosciences LLC. XC and CMS are inventors of a patent for vaccine development using herpesvirus trimeric gB proteins, and a pending patent using key envelope proteins combination in vaccine development.</p></sec><sec sec-type="disclaimer" id="s14"><title>Publisher&#8217;s Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Dr. James Gulley at CCR, NCI, NIH for reviewing the manuscript.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name><name name-style="western"><surname>Varmus</surname><given-names>H</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name></person-group>. <article-title>Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention</article-title>. <source>Sci Transl Med</source> (<year>2011</year>) <volume>3</volume>(<issue>107</issue>):<fpage>107fs7</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.3002878</pub-id><pub-id pub-id-type="pmcid">PMC3501269</pub-id><pub-id pub-id-type="pmid">22049067</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vetsika</surname><given-names>EK</given-names></name><name name-style="western"><surname>Callan</surname><given-names>M</given-names></name></person-group>. <article-title>Infectious Mononucleosis and Epstein-Barr Virus</article-title>. <source>Expert Rev Mol Med</source> (<year>2004</year>) <volume>6</volume>(<issue>23</issue>):<fpage>1</fpage>&#8211;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S1462399404008440</pub-id><pub-id pub-id-type="pmid">15541197</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name><name name-style="western"><surname>Mocarski</surname><given-names>ES</given-names></name><name name-style="western"><surname>Raab-Traub</surname><given-names>N</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name></person-group>. <article-title>The Need and Challenges for Development of an Epstein-Barr Virus Vaccine</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31 Suppl 2</volume>:<page-range>B194&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.041</pub-id><pub-id pub-id-type="pmcid">PMC3636506</pub-id><pub-id pub-id-type="pmid">23598481</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luzuriaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>JL</given-names></name></person-group>. <article-title>Infectious Mononucleosis</article-title>. <source>N Engl J Med</source> (<year>2010</year>) <volume>362</volume>(<issue>21</issue>):<fpage>1993</fpage>&#8211;<lpage>2000</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMcp1001116</pub-id><pub-id pub-id-type="pmid">20505178</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallee</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Evans</surname><given-names>AS</given-names></name><name name-style="western"><surname>Niederman</surname><given-names>JC</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>CM</given-names></name><name name-style="western"><surname>Voegtly j</surname><given-names>H</given-names></name></person-group>. <article-title>Infectious Mononucleosis at the United States Military Academy. A Prospective Study of a Single Class Over Four Years</article-title>. <source>Yale J Biol Med</source> (<year>1974</year>) <volume>47</volume>(<issue>3</issue>):<page-range>182&#8211;95</page-range>.<pub-id pub-id-type="pmcid">PMC2595096</pub-id><pub-id pub-id-type="pmid">4374836</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rea</surname><given-names>TD</given-names></name><name name-style="western"><surname>Russo</surname><given-names>JE</given-names></name><name name-style="western"><surname>Katon</surname><given-names>W</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>RL</given-names></name><name name-style="western"><surname>Buchwald</surname><given-names>DS</given-names></name></person-group>. <article-title>Prospective Study of the Natural History of Infectious Mononucleosis Caused by Epstein-Barr Virus</article-title>. <source>J Am Board Fam Pract</source> (<year>2001</year>) <volume>14</volume>(<issue>4</issue>):<page-range>234&#8211;42</page-range>.<pub-id pub-id-type="pmid">11458965</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name></person-group>. <article-title>Vaccine Development for Epstein-Barr Virus</article-title>. <source>Adv Exp Med Biol</source> (<year>2018</year>) <volume>1045</volume>:<page-range>477&#8211;93</page-range>. doi: <pub-id pub-id-type="doi">10.1007/978-981-10-7230-7_22</pub-id><pub-id pub-id-type="pmcid">PMC6328312</pub-id><pub-id pub-id-type="pmid">29896681</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neparidze</surname><given-names>N</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>J</given-names></name></person-group>. <article-title>Malignancies Associated With Epstein-Barr Virus: Pathobiology, Clinical Features, and Evolving Treatments</article-title>. <source>Clin Adv Hematol Oncol</source> (<year>2014</year>) <volume>12</volume>(<issue>6</issue>):<page-range>358&#8211;71</page-range>.<pub-id pub-id-type="pmid">25003566</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukayama</surname><given-names>M</given-names></name></person-group>. <article-title>Epstein-Barr Virus and Gastric Carcinoma</article-title>. <source>Pathol Int</source> (<year>2010</year>) <volume>60</volume>(<issue>5</issue>):<page-range>337&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1827.2010.02533.x</pub-id><pub-id pub-id-type="pmid">20518883</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name></person-group>. <article-title>The Global Health Burden of Infection-Associated Cancers in the Year 2002</article-title>. <source>Int J Cancer</source> (<year>2006</year>) <volume>118</volume>(<issue>12</issue>):<page-range>3030&#8211;44</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ijc.21731</pub-id><pub-id pub-id-type="pmid">16404738</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hjalgrim</surname><given-names>H</given-names></name><name name-style="western"><surname>Askling</surname><given-names>J</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>P</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosdahl</surname><given-names>N</given-names></name><name name-style="western"><surname>Storm</surname><given-names>HH</given-names></name><etal/></person-group>. <article-title>Risk of Hodgkin&#8217;s Disease and Other Cancers After Infectious Mononucleosis</article-title>. <source>J Natl Cancer Inst</source> (<year>2000</year>) <volume>92</volume>(<issue>18</issue>):<page-range>1522&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1093/jnci/92.18.1522</pub-id><pub-id pub-id-type="pmid">10995808</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dharnidharka</surname><given-names>VR</given-names></name></person-group>. <article-title>Comprehensive Review of Post-Organ Transplant Hematologic Cancers</article-title>. <source>Am J Transplant</source> (<year>2018</year>) <volume>18</volume>(<issue>3</issue>):<page-range>537&#8211;49</page-range>. doi: <pub-id pub-id-type="doi">10.1111/ajt.14603</pub-id><pub-id pub-id-type="pmid">29178667</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mansour</surname><given-names>Z</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>BP</given-names></name><name name-style="western"><surname>Evens</surname><given-names>AM</given-names></name></person-group>. <article-title>Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies</article-title>. <source>Curr Hematol Malig Rep</source> (<year>2013</year>) <volume>8</volume>(<issue>3</issue>):<page-range>173&#8211;83</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11899-013-0162-5</pub-id><pub-id pub-id-type="pmcid">PMC4831913</pub-id><pub-id pub-id-type="pmid">23737188</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AlDabbagh</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gitman</surname><given-names>MR</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name><name name-style="western"><surname>Humar</surname><given-names>A</given-names></name><name name-style="western"><surname>Rotstein</surname><given-names>C</given-names></name><name name-style="western"><surname>Husain</surname><given-names>S</given-names></name></person-group>. <article-title>The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review</article-title>. <source>Am J Transplant</source> (<year>2017</year>) <volume>17</volume>(<issue>3</issue>):<page-range>770&#8211;81</page-range>. doi: <pub-id pub-id-type="doi">10.1111/ajt.14020</pub-id><pub-id pub-id-type="pmid">27545492</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>H</given-names></name><name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Gotoh</surname><given-names>K</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kojima</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>EBV-Associated T/NK-Cell Lymphoproliferative Diseases in Nonimmunocompromised Hosts: Prospective Analysis of 108 Cases</article-title>. <source>Blood</source> (<year>2012</year>) <volume>119</volume>(<issue>3</issue>):<page-range>673&#8211;86</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2011-10-381921</pub-id><pub-id pub-id-type="pmid">22096243</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WS</given-names></name><name name-style="western"><surname>Ko</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MH</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name></person-group>. <article-title>Aggressive Natural Killer Cell Leukemia: Clinical Features and Treatment Outcome</article-title>. <source>Haematologica</source> (<year>2002</year>) <volume>87</volume>(<issue>12</issue>):<page-range>1343&#8211;5</page-range>.<pub-id pub-id-type="pmid">12495907</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iezzoni</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gaffey</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>LM</given-names></name></person-group>. <article-title>The Role of Epstein-Barr Virus in Lymphoepithelioma-Like Carcinomas</article-title>. <source>Am J Clin Pathol</source> (<year>1995</year>) <volume>103</volume>(<issue>3</issue>):<page-range>308&#8211;15</page-range>. doi: <pub-id pub-id-type="doi">10.1093/ajcp/103.3.308</pub-id><pub-id pub-id-type="pmid">7872253</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villegas</surname><given-names>E</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>O</given-names></name><name name-style="western"><surname>Sorlozano</surname><given-names>A</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>J</given-names></name></person-group>. <article-title>New Strategies and Patent Therapeutics in EBV-Associated Diseases</article-title>. <source>Mini Rev Med Chem</source> (<year>2010</year>) <volume>10</volume>(<issue>10</issue>):<page-range>914&#8211;27</page-range>. doi: <pub-id pub-id-type="doi">10.2174/138955710792007150</pub-id><pub-id pub-id-type="pmid">21034415</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matar</surname><given-names>CG</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>NT</given-names></name><name name-style="western"><surname>Speck</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Moormann</surname><given-names>AM</given-names></name></person-group>. <article-title>Does EBV Alter the Pathogenesis of Malaria</article-title>? <source>Parasite Immunol</source> (<year>2015</year>) <volume>37</volume>(<issue>9</issue>):<page-range>433&#8211;45</page-range>. doi: <pub-id pub-id-type="doi">10.1111/pim.12212</pub-id><pub-id pub-id-type="pmcid">PMC10290429</pub-id><pub-id pub-id-type="pmid">26121587</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imai</surname><given-names>K</given-names></name><name name-style="western"><surname>Kotani</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuda</surname><given-names>H</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ushida</surname><given-names>T</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Determination of the Cytokine Levels in Fetal Pleural Effusion and Their Association With Fetal/Neonatal Findings</article-title>. <source>Cytokine</source> (<year>2020</year>) <volume>127</volume>:<fpage>154945</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cyto.2019.154945</pub-id><pub-id pub-id-type="pmid">31805478</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasari</surname><given-names>V</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>D</given-names></name><name name-style="western"><surname>Neller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>R</given-names></name></person-group>. <article-title>Prophylactic and Therapeutic Strategies for Epstein-Barr Virus-Associated Diseases: Emerging Strategies for Clinical Development</article-title>. <source>Expert Rev Vaccines</source> (<year>2019</year>) <volume>18</volume>(<issue>5</issue>):<page-range>457&#8211;74</page-range>. doi: <pub-id pub-id-type="doi">10.1080/14760584.2019.1605906</pub-id><pub-id pub-id-type="pmid">30987475</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrell</surname><given-names>PJ</given-names></name></person-group>. <article-title>Epstein-Barr Virus and Cancer</article-title>. <source>Annu Rev Pathol</source> (<year>2019</year>) <volume>14</volume>:<fpage>29</fpage>&#8211;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012418-013023</pub-id><pub-id pub-id-type="pmid">30125149</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niederman</surname><given-names>JC</given-names></name><name name-style="western"><surname>McCollum</surname><given-names>RW</given-names></name><name name-style="western"><surname>Henle</surname><given-names>G</given-names></name><name name-style="western"><surname>Henle</surname><given-names>W</given-names></name></person-group>. <article-title>Infectious Mononucleosis. Clinical Manifestations in Relation to EB Virus Antibodies</article-title>. <source>JAMA</source> (<year>1968</year>) <volume>203</volume>(<issue>3</issue>):<page-range>205&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1001/jama.1968.03140030037009</pub-id><pub-id pub-id-type="pmid">4864269</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>SA</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>JO</given-names></name><name name-style="western"><surname>Jardetzky</surname><given-names>TS</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name></person-group>. <article-title>Fusing Structure and Function: A Structural View of the Herpesvirus Entry Machinery</article-title>. <source>Nat Rev Microbiol</source> (<year>2011</year>) <volume>9</volume>(<issue>5</issue>):<page-range>369&#8211;81</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro2548</pub-id><pub-id pub-id-type="pmcid">PMC3242325</pub-id><pub-id pub-id-type="pmid">21478902</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>LM</given-names></name></person-group>. <article-title>Epstein-Barr Virus Entry</article-title>. <source>J Virol</source> (<year>2007</year>) <volume>81</volume>(<issue>15</issue>):<page-range>7825&#8211;32</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00445-07</pub-id><pub-id pub-id-type="pmcid">PMC1951282</pub-id><pub-id pub-id-type="pmid">17459936</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon-Lowe</surname><given-names>C</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>M</given-names></name></person-group>. <article-title>Epstein Barr Virus Entry; Kissing and Conjugation</article-title>. <source>Curr Opin Virol</source> (<year>2014</year>) <volume>4</volume>:<fpage>78</fpage>&#8211;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.coviro.2013.12.001</pub-id><pub-id pub-id-type="pmid">24553068</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuhierl</surname><given-names>B</given-names></name><name name-style="western"><surname>Feederle</surname><given-names>R</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>W</given-names></name><name name-style="western"><surname>Delecluse</surname><given-names>HJ</given-names></name></person-group>. <article-title>Glycoprotein Gp110 of Epstein-Barr Virus Determines Viral Tropism and Efficiency of Infection</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2002</year>) <volume>99</volume>(<issue>23</issue>):<page-range>15036&#8211;41</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.232381299</pub-id><pub-id pub-id-type="pmcid">PMC137540</pub-id><pub-id pub-id-type="pmid">12409611</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heldwein</surname><given-names>EE</given-names></name><name name-style="western"><surname>Krummenacher</surname><given-names>C</given-names></name></person-group>. <article-title>Entry of Herpesviruses Into Mammalian Cells</article-title>. <source>Cell Mol Life Sci</source> (<year>2008</year>) <volume>65</volume>(<issue>11</issue>):<page-range>1653&#8211;68</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00018-008-7570-z</pub-id><pub-id pub-id-type="pmcid">PMC11131758</pub-id><pub-id pub-id-type="pmid">18351291</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>CO</given-names></name><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>L</given-names></name></person-group>. <article-title>Laser-Capture Microdissection of Oropharyngeal Epithelium Indicates Restriction of Epstein-Barr Virus Receptor/CD21 mRNA to Tonsil Epithelial Cells</article-title>. <source>J Oral Pathol Med</source> (<year>2008</year>) <volume>37</volume>(<issue>10</issue>):<page-range>626&#8211;33</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-0714.2008.00681.x</pub-id><pub-id pub-id-type="pmcid">PMC2584167</pub-id><pub-id pub-id-type="pmid">18710421</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkenbach</surname><given-names>M</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X</given-names></name><name name-style="western"><surname>Bradbury</surname><given-names>LE</given-names></name><name name-style="western"><surname>Tedder</surname><given-names>TF</given-names></name><name name-style="western"><surname>Kieff</surname><given-names>E</given-names></name></person-group>. <article-title>Characterization of an Epstein-Barr Virus Receptor on Human Epithelial Cells</article-title>. <source>J Exp Med</source> (<year>1992</year>) <volume>176</volume>(<issue>5</issue>):<page-range>1405&#8211;14</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.176.5.1405</pub-id><pub-id pub-id-type="pmcid">PMC2119421</pub-id><pub-id pub-id-type="pmid">1383386</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruo</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Takada</surname><given-names>K</given-names></name></person-group>. <article-title>Roles of Epstein-Barr Virus Glycoproteins Gp350 and Gp25 in the Infection of Human Epithelial Cells</article-title>. <source>J Gen Virol</source> (<year>2001</year>) <volume>82</volume>(<issue>Pt 10</issue>):<page-range>2373&#8211;83</page-range>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-82-10-2373</pub-id><pub-id pub-id-type="pmid">11562531</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fingeroth</surname><given-names>JD</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>ME</given-names></name><name name-style="western"><surname>Sage</surname><given-names>DR</given-names></name><name name-style="western"><surname>Hayman</surname><given-names>J</given-names></name><name name-style="western"><surname>Yates</surname><given-names>JL</given-names></name></person-group>. <article-title>CD21-Dependent Infection of an Epithelial Cell Line, 293, by Epstein-Barr Virus</article-title>. <source>J Virol</source> (<year>1999</year>) <volume>73</volume>(<issue>3</issue>):<page-range>2115&#8211;25</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.73.3.2115-2125.1999</pub-id><pub-id pub-id-type="pmcid">PMC104456</pub-id><pub-id pub-id-type="pmid">9971794</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>LM</given-names></name></person-group>. <article-title>Epstein-Barr Virus Replicating in Epithelial Cells</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2014</year>) <volume>111</volume>(<issue>46</issue>):<page-range>16242&#8211;3</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1418974111</pub-id><pub-id pub-id-type="pmcid">PMC4246291</pub-id><pub-id pub-id-type="pmid">25385596</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>SW</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>CM</given-names></name><name name-style="western"><surname>Pang</surname><given-names>PS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lo</surname><given-names>KW</given-names></name></person-group>. <article-title>The Biology of EBV Infection in Human Epithelial Cells</article-title>. <source>Semin Cancer Biol</source> (<year>2012</year>) <volume>22</volume>(<issue>2</issue>):<page-range>137&#8211;43</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.semcancer.2012.02.004</pub-id><pub-id pub-id-type="pmid">22497025</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>QX</given-names></name><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name><name name-style="western"><surname>Niedobitek</surname><given-names>G</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>CW</given-names></name><name name-style="western"><surname>Birkenbach</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Epstein-Barr Virus Infection and Replication in a Human Epithelial Cell System</article-title>. <source>Nature</source> (<year>1992</year>) <volume>356</volume>(<issue>6367</issue>):<page-range>347&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1038/356347a0</pub-id><pub-id pub-id-type="pmid">1312681</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name><name name-style="western"><surname>Jardetzky</surname><given-names>TS</given-names></name></person-group>. <article-title>Structure of a Trimeric Variant of the Epstein-Barr Virus Glycoprotein B</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2009</year>) <volume>106</volume>(<issue>8</issue>):<page-range>2880&#8211;5</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0810530106</pub-id><pub-id pub-id-type="pmcid">PMC2650359</pub-id><pub-id pub-id-type="pmid">19196955</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chesnokova</surname><given-names>LS</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>LM</given-names></name></person-group>. <article-title>Viral Entry</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2015</year>) <volume>391</volume>:<page-range>221&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.1007/978-3-319-22834-1_7</pub-id><pub-id pub-id-type="pmid">26428376</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hislop</surname><given-names>AD</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>GS</given-names></name><name name-style="western"><surname>Sauce</surname><given-names>D</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name></person-group>. <article-title>Cellular Responses to Viral Infection in Humans: Lessons From Epstein-Barr Virus</article-title>. <source>Annu Rev Immunol</source> (<year>2007</year>) <volume>25</volume>:<fpage>587</fpage>&#8211;<lpage>617</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.immunol.25.022106.141553</pub-id><pub-id pub-id-type="pmid">17378764</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name><name name-style="western"><surname>Long</surname><given-names>HM</given-names></name><name name-style="western"><surname>Palendira</surname><given-names>U</given-names></name><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name><name name-style="western"><surname>Hislop</surname><given-names>AD</given-names></name></person-group>. <article-title>Cellular Immune Controls Over Epstein-Barr Virus Infection: New Lessons From the Clinic and the Laboratory</article-title>. <source>Trends Immunol</source> (<year>2014</year>) <volume>35</volume>(<issue>4</issue>):<page-range>159&#8211;69</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.it.2014.01.003</pub-id><pub-id pub-id-type="pmid">24589417</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>GS</given-names></name><name name-style="western"><surname>Long</surname><given-names>HM</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name><name name-style="western"><surname>Hislop</surname><given-names>AD</given-names></name></person-group>. <article-title>The Immunology of Epstein-Barr Virus-Induced Disease</article-title>. <source>Annu Rev Immunol</source> (<year>2015</year>) <volume>33</volume>:<fpage>787</fpage>&#8211;<lpage>821</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112326</pub-id><pub-id pub-id-type="pmid">25706097</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon-Lowe</surname><given-names>C</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>A</given-names></name></person-group>. <article-title>The Global Landscape of EBV-Associated Tumors</article-title>. <source>Front Oncol</source> (<year>2019</year>) <volume>9</volume>:<elocation-id>713</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2019.00713</pub-id><pub-id pub-id-type="pmid">31448229</pub-id><pub-id pub-id-type="pmcid">PMC6691157</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayee</surname><given-names>R</given-names></name><name name-style="western"><surname>Ofori</surname><given-names>MEO</given-names></name><name name-style="western"><surname>Wright</surname><given-names>E</given-names></name><name name-style="western"><surname>Quaye</surname><given-names>O</given-names></name></person-group>. <article-title>Epstein Barr Virus Associated Lymphomas and Epithelia Cancers in Humans</article-title>. <source>J Cancer</source> (<year>2020</year>) <volume>11</volume>(<issue>7</issue>):<page-range>1737&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.7150/jca.37282</pub-id><pub-id pub-id-type="pmcid">PMC7052849</pub-id><pub-id pub-id-type="pmid">32194785</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fugl</surname><given-names>A</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>CL</given-names></name></person-group>. <article-title>Epstein-Barr Virus and Its Association With Disease - a Review of Relevance to General Practice</article-title>. <source>BMC Fam Pract</source> (<year>2019</year>) <volume>20</volume>(<issue>1</issue>):<fpage>62</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12875-019-0954-3</pub-id><pub-id pub-id-type="pmid">31088382</pub-id><pub-id pub-id-type="pmcid">PMC6518816</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunmire</surname><given-names>SK</given-names></name><name name-style="western"><surname>Verghese</surname><given-names>PS</given-names></name><name name-style="western"><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr.</suffix></name></person-group><article-title>Primary Epstein-Barr Virus Infection</article-title>. <source>J Clin Virol</source> (<year>2018</year>) <volume>102</volume>:<fpage>84</fpage>&#8211;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcv.2018.03.001</pub-id><pub-id pub-id-type="pmid">29525635</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chandran</surname><given-names>B</given-names></name><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>L</given-names></name></person-group>. <article-title>Gammaherpesviruses Entry and Early Events During Infection</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Arvin</surname><given-names>A</given-names></name><name name-style="western"><surname>Campadelli-Fiume</surname><given-names>G</given-names></name><name name-style="western"><surname>Mocarski</surname><given-names>E</given-names></name><name name-style="western"><surname>Moore</surname><given-names>PS</given-names></name><name name-style="western"><surname>Roizman</surname><given-names>B</given-names></name><name name-style="western"><surname>Whitley</surname><given-names>R</given-names></name><etal/></person-group>. editors. <source>Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis</source>. <publisher-loc>Cambridge University Press</publisher-loc> (<year>2007</year>).<pub-id pub-id-type="pmid">21348095</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tattevin</surname><given-names>P</given-names></name><name name-style="western"><surname>Le Tulzo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Minjolle</surname><given-names>S</given-names></name><name name-style="western"><surname>Person</surname><given-names>A</given-names></name><name name-style="western"><surname>Chapplain</surname><given-names>JM</given-names></name><name name-style="western"><surname>Arvieux</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Increasing Incidence of Severe Epstein-Barr Virus-Related Infectious Mononucleosis: Surveillance Study</article-title>. <source>J Clin Microbiol</source> (<year>2006</year>) <volume>44</volume>(<issue>5</issue>):<page-range>1873&#8211;4</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JCM.44.5.1873-1874.2006</pub-id><pub-id pub-id-type="pmcid">PMC1479173</pub-id><pub-id pub-id-type="pmid">16672427</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rostgaard</surname><given-names>K</given-names></name><name name-style="western"><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Jarrett</surname><given-names>R</given-names></name><name name-style="western"><surname>Erikstrup</surname><given-names>C</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>O</given-names></name><name name-style="western"><surname>Ullum</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Primary Epstein-Barr Virus Infection With and Without Infectious Mononucleosis</article-title>. <source>PloS One</source> (<year>2019</year>) <volume>14</volume>(<issue>12</issue>):<fpage>e0226436</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0226436</pub-id><pub-id pub-id-type="pmid">31846480</pub-id><pub-id pub-id-type="pmcid">PMC6917282</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayasooriya</surname><given-names>S</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>TI</given-names></name><name name-style="western"><surname>Njie-jobe</surname><given-names>J</given-names></name><name name-style="western"><surname>Sanyang</surname><given-names>C</given-names></name><name name-style="western"><surname>Leese</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bell</surname><given-names>AI</given-names></name><etal/></person-group>. <article-title>Early Virological and Immunological Events in Asymptomatic Epstein-Barr Virus Infection in African Children</article-title>. <source>PloS Pathog</source> (<year>2015</year>) <volume>11</volume>(<issue>3</issue>):<fpage>e1004746</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1004746</pub-id><pub-id pub-id-type="pmid">25816224</pub-id><pub-id pub-id-type="pmcid">PMC4376400</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Pachnio</surname><given-names>A</given-names></name><name name-style="western"><surname>Pedroza-Pacheco</surname><given-names>I</given-names></name><name name-style="western"><surname>Leese</surname><given-names>AM</given-names></name><name name-style="western"><surname>Begum</surname><given-names>J</given-names></name><name name-style="western"><surname>Long</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Asymptomatic Primary Infection With Epstein-Barr Virus: Observations on Young Adult Cases</article-title>. <source>J Virol</source> (<year>2017</year>) <volume>91</volume>(<issue>21</issue>). doi: <pub-id pub-id-type="doi">10.1128/JVI.00382-17</pub-id><pub-id pub-id-type="pmcid">PMC5640854</pub-id><pub-id pub-id-type="pmid">28835490</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odame</surname><given-names>J</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J</given-names></name><name name-style="western"><surname>Khodai-Booran</surname><given-names>N</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>S</given-names></name><name name-style="western"><surname>Mazzulli</surname><given-names>T</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Correlates of Illness Severity in Infectious Mononucleosis</article-title>. <source>Can J Infect Dis Med Microbiol</source> (<year>2014</year>) <volume>25</volume>(<issue>5</issue>):<page-range>277&#8211;80</page-range>. doi: <pub-id pub-id-type="doi">10.1155/2014/514164</pub-id><pub-id pub-id-type="pmcid">PMC4211352</pub-id><pub-id pub-id-type="pmid">25371691</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>H</given-names></name><name name-style="western"><surname>Macsween</surname><given-names>K</given-names></name><name name-style="western"><surname>McAulay</surname><given-names>K</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>C</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>N</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Analysis of Immune Activation and Clinical Events in Acute Infectious Mononucleosis</article-title>. <source>J Infect Dis</source> (<year>2004</year>) <volume>190</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1086/421276</pub-id><pub-id pub-id-type="pmid">15195244</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Leung</surname><given-names>CS</given-names></name><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name></person-group>. <article-title>Animal Models of Epstein Barr Virus Infection</article-title>. <source>J Immunol Methods</source> (<year>2014</year>) <volume>410</volume>:<page-range>80&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jim.2014.04.009</pub-id><pub-id pub-id-type="pmid">24815603</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glynn</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Mackle</surname><given-names>T</given-names></name><name name-style="western"><surname>Kinsella</surname><given-names>J</given-names></name></person-group>. <article-title>Upper Airway Obstruction in Infectious Mononucleosis</article-title>. <source>Eur J Emerg Med</source> (<year>2007</year>) <volume>14</volume>(<issue>1</issue>):<page-range>41&#8211;2</page-range>. doi: <pub-id pub-id-type="doi">10.1097/01.mej.0000224431.36376.71</pub-id><pub-id pub-id-type="pmid">17198326</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elgui de Oliveira</surname><given-names>D</given-names></name><name name-style="western"><surname>Muller-Coan</surname><given-names>BG</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>JS</given-names></name></person-group>. <article-title>Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers</article-title>. <source>Trends Microbiol</source> (<year>2016</year>) <volume>24</volume>(<issue>8</issue>):<page-range>649&#8211;64</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2016.03.008</pub-id><pub-id pub-id-type="pmcid">PMC5489061</pub-id><pub-id pub-id-type="pmid">27068530</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Castro</surname><given-names>FA</given-names></name><name name-style="western"><surname>Hu</surname><given-names>JK</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>H</given-names></name></person-group>. <article-title>Epstein-Barr Virus Infection and Gastric Cancer: A Systematic Review</article-title>. <source>Med (Baltimore)</source> (<year>2015</year>) <volume>94</volume>(<issue>20</issue>):<fpage>e792</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000000792</pub-id><pub-id pub-id-type="pmcid">PMC4602887</pub-id><pub-id pub-id-type="pmid">25997049</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Han</surname><given-names>SH</given-names></name><name name-style="western"><surname>An</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>ES</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name></person-group>. <article-title>Clinicopathological and Molecular Characteristics of Epstein-Barr Virus-Associated Gastric Carcinoma: A Meta-Analysis</article-title>. <source>J Gastroenterol Hepatol</source> (<year>2009</year>) <volume>24</volume>(<issue>3</issue>):<page-range>354&#8211;65</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1746.2009.05775.x</pub-id><pub-id pub-id-type="pmid">19335785</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mawson</surname><given-names>AR</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>S</given-names></name></person-group>. <article-title>Malaria, Epstein-Barr Virus Infection and the Pathogenesis of Burkitt&#8217;s Lymphoma</article-title>. <source>Int J Cancer</source> (<year>2017</year>) <volume>141</volume>(<issue>9</issue>):<page-range>1849&#8211;55</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ijc.30885</pub-id><pub-id pub-id-type="pmid">28707393</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rochford</surname><given-names>R</given-names></name><name name-style="western"><surname>Moormann</surname><given-names>AM</given-names></name></person-group>. <article-title>Burkitt&#8217;s Lymphoma</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2015</year>) <volume>390</volume>(<issue>Pt 1</issue>):<page-range>267&#8211;85</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-3-319-22822-8_11</pub-id><pub-id pub-id-type="pmid">26424650</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bornkamm</surname><given-names>GW</given-names></name></person-group>. <article-title>Epstein-Barr Virus and the Pathogenesis of Burkitt&#8217;s Lymphoma: More Questions Than Answers</article-title>. <source>Int J Cancer</source> (<year>2009</year>) <volume>124</volume>(<issue>8</issue>):<page-range>1745&#8211;55</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ijc.24223</pub-id><pub-id pub-id-type="pmid">19165855</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanbhag</surname><given-names>S</given-names></name><name name-style="western"><surname>Ambinder</surname><given-names>RF</given-names></name></person-group>. <article-title>Hodgkin Lymphoma: A Review and Update on Recent Progress</article-title>. <source>CA Cancer J Clin</source> (<year>2018</year>) <volume>68</volume>(<issue>2</issue>):<page-range>116&#8211;32</page-range>. doi: <pub-id pub-id-type="doi">10.3322/caac.21438</pub-id><pub-id pub-id-type="pmcid">PMC5842098</pub-id><pub-id pub-id-type="pmid">29194581</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambinder</surname><given-names>RF</given-names></name></person-group>. <article-title>Epstein-Barr Virus and Hodgkin Lymphoma</article-title>. <source>Hematol Am Soc Hematol Educ Program</source> (<year>2007</year>), <page-range>204&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1182/asheducation-2007.1.204</pub-id><pub-id pub-id-type="pmid">18024631</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>LM</given-names></name><name name-style="western"><surname>Movahed</surname><given-names>LA</given-names></name><name name-style="western"><surname>Warnke</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sklar</surname><given-names>J</given-names></name></person-group>. <article-title>Detection of Epstein-Barr Viral Genomes in Reed-Sternberg Cells of Hodgkin&#8217;s Disease</article-title>. <source>N Engl J Med</source> (<year>1989</year>) <volume>320</volume>(<issue>8</issue>):<page-range>502&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJM198902233200806</pub-id><pub-id pub-id-type="pmid">2536894</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anagnostopoulos</surname><given-names>I</given-names></name><name name-style="western"><surname>Herbst</surname><given-names>H</given-names></name><name name-style="western"><surname>Niedobitek</surname><given-names>G</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H</given-names></name></person-group>. <article-title>Demonstration of Monoclonal EBV Genomes in Hodgkin&#8217;s Disease and Ki-1-Positive Anaplastic Large Cell Lymphoma by Combined Southern Blot and in Situ Hybridization</article-title>. <source>Blood</source> (<year>1989</year>) <volume>74</volume>(<issue>2</issue>):<page-range>810&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V74.2.810.810</pub-id><pub-id pub-id-type="pmid">2546633</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rooney</surname><given-names>CM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CY</given-names></name><name name-style="western"><surname>Loftin</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Krance</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Use of Gene-Modified Virus-Specific T Lymphocytes to Control Epstein-Barr-Virus-Related Lymphoproliferation</article-title>. <source>Lancet</source> (<year>1995</year>) <volume>345</volume>(<issue>8941</issue>):<fpage>9</fpage>&#8211;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(95)91150-2</pub-id><pub-id pub-id-type="pmid">7799740</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rooney</surname><given-names>CM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CY</given-names></name><name name-style="western"><surname>Loftin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sixbey</surname><given-names>JW</given-names></name><name name-style="western"><surname>Gan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus-Induced Lymphoma in Allogeneic Transplant Recipients</article-title>. <source>Blood</source> (<year>1998</year>) <volume>92</volume>(<issue>5</issue>):<page-range>1549&#8211;55</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V92.5.1549.417k32_1549_1555</pub-id><pub-id pub-id-type="pmid">9716582</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heslop</surname><given-names>HE</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CY</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CA</given-names></name><name name-style="western"><surname>Loftin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Krance</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes</article-title>. <source>Nat Med</source> (<year>1996</year>) <volume>2</volume>(<issue>5</issue>):<page-range>551&#8211;5</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm0596-551</pub-id><pub-id pub-id-type="pmid">8616714</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heslop</surname><given-names>HE</given-names></name><name name-style="western"><surname>Slobod</surname><given-names>KS</given-names></name><name name-style="western"><surname>Pule</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hale</surname><given-names>GA</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>A</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Long-Term Outcome of EBV-Specific T-Cell Infusions to Prevent or Treat EBV-Related Lymphoproliferative Disease in Transplant Recipients</article-title>. <source>Blood</source> (<year>2010</year>) <volume>115</volume>(<issue>5</issue>):<page-range>925&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2009-08-239186</pub-id><pub-id pub-id-type="pmcid">PMC2817637</pub-id><pub-id pub-id-type="pmid">19880495</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottschalk</surname><given-names>S</given-names></name><name name-style="western"><surname>Rooney</surname><given-names>CM</given-names></name></person-group>. <article-title>Adoptive T-Cell Immunotherapy</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2015</year>) <volume>391</volume>:<page-range>427&#8211;54</page-range>. doi: <pub-id pub-id-type="doi">10.1007/978-3-319-22834-1_15</pub-id><pub-id pub-id-type="pmcid">PMC4655436</pub-id><pub-id pub-id-type="pmid">26428384</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sashihara</surname><given-names>J</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Krogmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Burbelo</surname><given-names>PD</given-names></name><name name-style="western"><surname>Coffield</surname><given-names>VM</given-names></name><etal/></person-group>. <article-title>Soluble Rhesus Lymphocryptovirus Gp350 Protects Against Infection and Reduces Viral Loads in Animals That Become Infected With Virus After Challenge</article-title>. <source>PloS Pathog</source> (<year>2011</year>) <volume>7</volume>(<issue>10</issue>):<fpage>e1002308</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1002308</pub-id><pub-id pub-id-type="pmid">22028652</pub-id><pub-id pub-id-type="pmcid">PMC3197588</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>North</surname><given-names>JR</given-names></name></person-group>. <article-title>Comparative Immunogenicity Studies on Epstein-Barr Virus Membrane Antigen (MA) Gp340 With Novel Adjuvants in Mice, Rabbits, and Cotton-Top Tamarins</article-title>. <source>J Med Virol</source> (<year>1984</year>) <volume>13</volume>(<issue>3</issue>):<page-range>281&#8211;92</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jmv.1890130310</pub-id><pub-id pub-id-type="pmid">6327902</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Allison</surname><given-names>AC</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Scullion</surname><given-names>FT</given-names></name><name name-style="western"><surname>Byars</surname><given-names>NE</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name></person-group>. <article-title>Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use</article-title>. <source>J Med Virol</source> (<year>1989</year>) <volume>29</volume>(<issue>1</issue>):<page-range>74&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jmv.1890290114</pub-id><pub-id pub-id-type="pmid">2555448</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Tarlton</surname><given-names>J</given-names></name><name name-style="western"><surname>Mackett</surname><given-names>M</given-names></name><name name-style="western"><surname>Conway</surname><given-names>M</given-names></name><name name-style="western"><surname>Arrand</surname><given-names>JR</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PE</given-names></name><etal/></person-group>. <article-title>Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope Glycoprotein Gp340 Produced From a Bovine Papillomavirus Expression Vector</article-title>. <source>J Gen Virol</source> (<year>1992</year>) <volume>73</volume>(<issue> Pt 2</issue>):<page-range>449&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-73-2-449</pub-id><pub-id pub-id-type="pmid">1311367</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>C</given-names></name><name name-style="western"><surname>Naylor</surname><given-names>BA</given-names></name><name name-style="western"><surname>Mackett</surname><given-names>M</given-names></name><name name-style="western"><surname>Arrand</surname><given-names>JR</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>BE</given-names></name><name name-style="western"><surname>Wedderburn</surname><given-names>N</given-names></name></person-group>. <article-title>Immunization of Common Marmosets With Epstein-Barr Virus (EBV) Envelope Glycoprotein Gp340: Effect on Viral Shedding Following EBV Challenge</article-title>. <source>J Med Virol</source> (<year>1998</year>) <volume>55</volume>(<issue>4</issue>):<page-range>255&#8211;61</page-range>. doi: <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-9071(199808)55:4&amp;#x0003c;255::AID-JMV1&amp;#x0003e;3.0.CO;2-#</pub-id><pub-id pub-id-type="pmid">9661832</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackett</surname><given-names>M</given-names></name><name name-style="western"><surname>Cox</surname><given-names>C</given-names></name><name name-style="western"><surname>Pepper</surname><given-names>SD</given-names></name><name name-style="western"><surname>Lees</surname><given-names>JF</given-names></name><name name-style="western"><surname>Naylor</surname><given-names>BA</given-names></name><name name-style="western"><surname>Wedderburn</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Immunisation of Common Marmosets With Vaccinia Virus Expressing Epstein-Barr Virus (EBV) Gp340 and Challenge With EBV</article-title>. <source>J Med Virol</source> (<year>1996</year>) <volume>50</volume>(<issue>3</issue>):<page-range>263&#8211;71</page-range>. doi: <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-9071(199611)50:3&amp;#x0003c;263::AID-JMV9&amp;#x0003e;3.0.CO;2-7</pub-id><pub-id pub-id-type="pmid">8923292</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragot</surname><given-names>T</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PE</given-names></name><name name-style="western"><surname>Perricaudet</surname><given-names>M</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name></person-group>. <article-title>Replication-Defective Recombinant Adenovirus Expressing the Epstein-Barr Virus (EBV) Envelope Glycoprotein Gp340/220 Induces Protective Immunity Against EBV-Induced Lymphomas in the Cottontop Tamarin</article-title>. <source>J Gen Virol</source> (<year>1993</year>) <volume>74</volume>(<issue> Pt 3</issue>):<page-range>501&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-74-3-501</pub-id><pub-id pub-id-type="pmid">8383183</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Mackett</surname><given-names>M</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Arrand</surname><given-names>JR</given-names></name><name name-style="western"><surname>Scullion</surname><given-names>FT</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name></person-group>. <article-title>Recombinant Vaccinia Virus Expressing Epstein-Barr Virus Glycoprotein Gp340 Protects Cottontop Tamarins Against EB Virus-Induced Malignant Lymphomas</article-title>. <source>J Med Virol</source> (<year>1988</year>) <volume>25</volume>(<issue>2</issue>):<page-range>189&#8211;95</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jmv.1890250209</pub-id><pub-id pub-id-type="pmid">2839612</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yajima</surname><given-names>M</given-names></name><name name-style="western"><surname>Imadome</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Terashima</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A New Humanized Mouse Model of Epstein-Barr Virus Infection That Reproduces Persistent Infection, Lymphoproliferative Disorder, and Cell-Mediated and Humoral Immune Responses</article-title>. <source>J Infect Dis</source> (<year>2008</year>) <volume>198</volume>(<issue>5</issue>):<page-range>673&#8211;82</page-range>. doi: <pub-id pub-id-type="doi">10.1086/590502</pub-id><pub-id pub-id-type="pmid">18627269</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>K</given-names></name><name name-style="western"><surname>Misawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Nie</surname><given-names>C</given-names></name><name name-style="western"><surname>Satou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Iwakiri</surname><given-names>D</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A Novel Animal Model of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Humanized Mice</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>(<issue>21</issue>):<page-range>5663&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2010-09-305979</pub-id><pub-id pub-id-type="pmid">21467545</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swerdlow</surname><given-names>SH</given-names></name><name name-style="western"><surname>Campo</surname><given-names>E</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>SA</given-names></name><name name-style="western"><surname>Harris</surname><given-names>NL</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H</given-names></name><name name-style="western"><surname>Siebert</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms</article-title>. <source>Blood</source> (<year>2016</year>) <volume>127</volume>(<issue>20</issue>):<page-range>2375&#8211;90</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2016-01-643569</pub-id><pub-id pub-id-type="pmcid">PMC4874220</pub-id><pub-id pub-id-type="pmid">26980727</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenze</surname><given-names>D</given-names></name><name name-style="western"><surname>Leoncini</surname><given-names>L</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>M</given-names></name><name name-style="western"><surname>Volinia</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CG</given-names></name><name name-style="western"><surname>Amato</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The Different Epidemiologic Subtypes of Burkitt Lymphoma Share a Homogenous Micro RNA Profile Distinct From Diffuse Large B-Cell Lymphoma</article-title>. <source>Leukemia</source> (<year>2011</year>) <volume>25</volume>(<issue>12</issue>):<page-range>1869&#8211;76</page-range>. doi: <pub-id pub-id-type="doi">10.1038/leu.2011.156</pub-id><pub-id pub-id-type="pmcid">PMC3902789</pub-id><pub-id pub-id-type="pmid">21701491</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon-Lowe</surname><given-names>C</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name><name name-style="western"><surname>Bell</surname><given-names>AI</given-names></name></person-group>. <article-title>Epstein-Barr Virus-Associated Lymphomas</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source> (<year>2017</year>) <volume>372</volume>(<issue>1732</issue>). doi: <pub-id pub-id-type="doi">10.1098/rstb.2016.0271</pub-id><pub-id pub-id-type="pmcid">PMC5597738</pub-id><pub-id pub-id-type="pmid">28893938</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Queiroga</surname><given-names>EM</given-names></name><name name-style="western"><surname>Gualco</surname><given-names>G</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>LM</given-names></name><name name-style="western"><surname>Dittmer</surname><given-names>DP</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>I</given-names></name><name name-style="western"><surname>Klumb</surname><given-names>CE</given-names></name><etal/></person-group>. <article-title>Burkitt Lymphoma in Brazil is Characterized by Geographically Distinct Clinicopathologic Features</article-title>. <source>Am J Clin Pathol</source> (<year>2008</year>) <volume>130</volume>(<issue>6</issue>):<page-range>946&#8211;56</page-range>. doi: <pub-id pub-id-type="doi">10.1309/AJCP64YOHAWLUMPK</pub-id><pub-id pub-id-type="pmcid">PMC2866005</pub-id><pub-id pub-id-type="pmid">19019773</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gloghini</surname><given-names>A</given-names></name><name name-style="western"><surname>Dolcetti</surname><given-names>R</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>A</given-names></name></person-group>. <article-title>Lymphomas Occurring Specifically in HIV-Infected Patients: From Pathogenesis to Pathology</article-title>. <source>Semin Cancer Biol</source> (<year>2013</year>) <volume>23</volume>(<issue>6</issue>):<page-range>457&#8211;67</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.semcancer.2013.08.004</pub-id><pub-id pub-id-type="pmid">23999127</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magrath</surname><given-names>I</given-names></name></person-group>. <article-title>Epidemiology: Clues to the Pathogenesis of Burkitt Lymphoma</article-title>. <source>Br J Haematol</source> (<year>2012</year>) <volume>156</volume>(<issue>6</issue>):<page-range>744&#8211;56</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.09013.x</pub-id><pub-id pub-id-type="pmid">22260300</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allday</surname><given-names>MJ</given-names></name></person-group>. <article-title>How Does Epstein-Barr Virus (EBV) Complement the Activation of Myc in the Pathogenesis of Burkitt&#8217;s Lymphoma</article-title>? <source>Semin Cancer Biol</source> (<year>2009</year>) <volume>19</volume>(<issue>6</issue>):<page-range>366&#8211;76</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.semcancer.2009.07.007</pub-id><pub-id pub-id-type="pmcid">PMC3770905</pub-id><pub-id pub-id-type="pmid">19635566</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>SW</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lo</surname><given-names>KW</given-names></name></person-group>. <article-title>Epstein-Barr Virus Infection and Nasopharyngeal Carcinoma</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source> (<year>2017</year>) <volume>372</volume>(<issue>1732</issue>). doi: <pub-id pub-id-type="doi">10.1098/rstb.2016.0270</pub-id><pub-id pub-id-type="pmcid">PMC5597737</pub-id><pub-id pub-id-type="pmid">28893937</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirchmaier</surname><given-names>AL</given-names></name><name name-style="western"><surname>Sugden</surname><given-names>B</given-names></name></person-group>. <article-title>Dominant-Negative Inhibitors of EBNA-1 of Epstein-Barr Virus</article-title>. <source>J Virol</source> (<year>1997</year>) <volume>71</volume>(<issue>3</issue>):<page-range>1766&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1128/jvi.71.3.1766-1775.1997</pub-id><pub-id pub-id-type="pmcid">PMC191245</pub-id><pub-id pub-id-type="pmid">9032305</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorley-Lawson</surname><given-names>D</given-names></name><name name-style="western"><surname>Deitsch</surname><given-names>KW</given-names></name><name name-style="western"><surname>Duca</surname><given-names>KA</given-names></name><name name-style="western"><surname>Torgbor</surname><given-names>C</given-names></name></person-group>. <article-title>The Link Between Plasmodium Falciparum Malaria and Endemic Burkitt&#8217;s Lymphoma-New Insight Into a 50-Year-Old Enigma</article-title>. <source>PloS Pathog</source> (<year>2016</year>) <volume>12</volume>(<issue>1</issue>):<fpage>e1005331</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1005331</pub-id><pub-id pub-id-type="pmid">26794909</pub-id><pub-id pub-id-type="pmcid">PMC4721646</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carbone</surname><given-names>A</given-names></name><name name-style="western"><surname>Cesarman</surname><given-names>E</given-names></name><name name-style="western"><surname>Spina</surname><given-names>M</given-names></name><name name-style="western"><surname>Gloghini</surname><given-names>A</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>TF</given-names></name></person-group>. <article-title>HIV-Associated Lymphomas and Gamma-Herpesviruses</article-title>. <source>Blood</source> (<year>2009</year>) <volume>113</volume>(<issue>6</issue>):<page-range>1213&#8211;24</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2008-09-180315</pub-id><pub-id pub-id-type="pmid">18955561</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallesen</surname><given-names>G</given-names></name><name name-style="western"><surname>Hamilton-Dutoit</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>M</given-names></name><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name></person-group>. <article-title>Expression of Epstein-Barr Virus Latent Gene Products in Tumour Cells of Hodgkin&#8217;s Disease</article-title>. <source>Lancet</source> (<year>1991</year>) <volume>337</volume>(<issue>8737</issue>):<page-range>320&#8211;2</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0140-6736(91)90943-J</pub-id><pub-id pub-id-type="pmid">1671232</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Lin</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ambinder</surname><given-names>RF</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>RF</given-names></name><name name-style="western"><surname>Brousset</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Epstein-Barr Virus-Associated Hodgkin&#8217;s Disease: Epidemiologic Characteristics in International Data</article-title>. <source>Int J Cancer</source> (<year>1997</year>) <volume>70</volume>(<issue>4</issue>):<page-range>375&#8211;82</page-range>. doi: <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0215(19970207)70:4&amp;#x0003c;375::AID-IJC1&amp;#x0003e;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">9033642</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vrzalikova</surname><given-names>K</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>E</given-names></name><name name-style="western"><surname>Vockerodt</surname><given-names>M</given-names></name><name name-style="western"><surname>Perry</surname><given-names>T</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Co-Expression of the Epstein-Barr Virus-Encoded Latent Membrane Proteins and the Pathogenesis of Classic Hodgkin Lymphoma</article-title>. <source>Cancers (Basel)</source> (<year>2018</year>) <volume>10</volume>(<issue>9</issue>). doi: <pub-id pub-id-type="doi">10.3390/cancers10090285</pub-id><pub-id pub-id-type="pmcid">PMC6162670</pub-id><pub-id pub-id-type="pmid">30149502</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuppers</surname><given-names>R</given-names></name><name name-style="western"><surname>Kanzler</surname><given-names>H</given-names></name><name name-style="western"><surname>Hansmann</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rajewsky</surname><given-names>K</given-names></name></person-group>. <article-title>Single Cell Analysis of Hodgkin/Reed-Sternberg Cells</article-title>. <source>Ann Oncol</source> (<year>1996</year>) <volume>7 Suppl 4</volume>:<fpage>27</fpage>&#8211;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/7.suppl_4.S27</pub-id><pub-id pub-id-type="pmid">8836405</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanzler</surname><given-names>H</given-names></name><name name-style="western"><surname>Kuppers</surname><given-names>R</given-names></name><name name-style="western"><surname>Hansmann</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rajewsky</surname><given-names>K</given-names></name></person-group>. <article-title>Hodgkin and Reed-Sternberg Cells in Hodgkin&#8217;s Disease Represent the Outgrowth of a Dominant Tumor Clone Derived From (Crippled) Germinal Center B Cells</article-title>. <source>J Exp Med</source> (<year>1996</year>) <volume>184</volume>(<issue>4</issue>):<page-range>1495&#8211;505</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.184.4.1495</pub-id><pub-id pub-id-type="pmcid">PMC2192840</pub-id><pub-id pub-id-type="pmid">8879220</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuppers</surname><given-names>R</given-names></name><name name-style="western"><surname>Rajewsky</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Simons</surname><given-names>G</given-names></name><name name-style="western"><surname>Laumann</surname><given-names>R</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Hodgkin&#8217;s Disease: Clonal Ig Gene Rearrangements in Hodgkin and Reed-Sternberg Cells Picked From Histological Sections</article-title>. <source>Ann N Y Acad Sci</source> (<year>1995</year>) <volume>764</volume>:<page-range>523&#8211;4</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1749-6632.1995.tb55877.x</pub-id><pub-id pub-id-type="pmid">7486580</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bargou</surname><given-names>RC</given-names></name><name name-style="western"><surname>Emmerich</surname><given-names>F</given-names></name><name name-style="western"><surname>Krappmann</surname><given-names>D</given-names></name><name name-style="western"><surname>Bommert</surname><given-names>K</given-names></name><name name-style="western"><surname>Mapara</surname><given-names>MY</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Constitutive Nuclear factor-kappaB-RelA Activation is Required for Proliferation and Survival of Hodgkin&#8217;s Disease Tumor Cells</article-title>. <source>J Clin Invest</source> (<year>1997</year>) <volume>100</volume>(<issue>12</issue>):<page-range>2961&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI119849</pub-id><pub-id pub-id-type="pmcid">PMC508507</pub-id><pub-id pub-id-type="pmid">9399941</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutton</surname><given-names>A</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>GM</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>CW</given-names></name><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name><name name-style="western"><surname>Murray</surname><given-names>PG</given-names></name></person-group>. <article-title>Constitutive Activation of Phosphatidyl-Inositide 3 Kinase Contributes to the Survival of Hodgkin&#8217;s Lymphoma Cells Through a Mechanism Involving Akt Kinase and mTOR</article-title>. <source>J Pathol</source> (<year>2005</year>) <volume>205</volume>(<issue>4</issue>):<fpage>498</fpage>&#8211;<lpage>506</lpage>. doi: <pub-id pub-id-type="doi">10.1002/path.1725</pub-id><pub-id pub-id-type="pmid">15714459</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gires</surname><given-names>O</given-names></name><name name-style="western"><surname>Kohlhuber</surname><given-names>F</given-names></name><name name-style="western"><surname>Kilger</surname><given-names>E</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>M</given-names></name><name name-style="western"><surname>Kieser</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Latent Membrane Protein 1 of Epstein-Barr Virus Interacts With JAK3 and Activates STAT Proteins</article-title>. <source>EMBO J</source> (<year>1999</year>) <volume>18</volume>(<issue>11</issue>):<page-range>3064&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.1093/emboj/18.11.3064</pub-id><pub-id pub-id-type="pmcid">PMC1171388</pub-id><pub-id pub-id-type="pmid">10357818</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huen</surname><given-names>DS</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>SA</given-names></name><name name-style="western"><surname>Croom-Carter</surname><given-names>D</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>M</given-names></name></person-group>. <article-title>The Epstein-Barr Virus Latent Membrane Protein-1 (LMP1) Mediates Activation of NF-Kappa B and Cell Surface Phenotype via Two Effector Regions in Its Carboxy-Terminal Cytoplasmic Domain</article-title>. <source>Oncogene</source> (<year>1995</year>) <volume>10</volume>(<issue>3</issue>):<page-range>549&#8211;60</page-range>.<pub-id pub-id-type="pmid">7845680</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holtick</surname><given-names>U</given-names></name><name name-style="western"><surname>Vockerodt</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinkert</surname><given-names>D</given-names></name><name name-style="western"><surname>Schoof</surname><given-names>N</given-names></name><name name-style="western"><surname>Sturzenhofecker</surname><given-names>B</given-names></name><name name-style="western"><surname>Kussebi</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>STAT3 is Essential for Hodgkin Lymphoma Cell Proliferation and is a Target of Tyrphostin AG17 Which Confers Sensitization for Apoptosis</article-title>. <source>Leukemia</source> (<year>2005</year>) <volume>19</volume>(<issue>6</issue>):<page-range>936&#8211;44</page-range>. doi: <pub-id pub-id-type="doi">10.1038/sj.leu.2403750</pub-id><pub-id pub-id-type="pmid">15912144</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eliopoulos</surname><given-names>AG</given-names></name><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name></person-group>. <article-title>Activation of the Cjun N-Terminal Kinase (JNK) Pathway by the Epstein-Barr Virus-Encoded Latent Membrane Protein 1 (LMP1)</article-title>. <source>Oncogene</source> (<year>1998</year>) <volume>16</volume>(<issue>13</issue>):<page-range>1731&#8211;42</page-range>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1201694</pub-id><pub-id pub-id-type="pmid">9582021</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laherty</surname><given-names>CD</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Opipari</surname><given-names>AW</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>VM</given-names></name></person-group>. <article-title>The Epstein-Barr Virus LMP1 Gene Product Induces A20 Zinc Finger Protein Expression by Activating Nuclear Factor Kappa B</article-title>. <source>J Biol Chem</source> (<year>1992</year>) <volume>267</volume>(<issue>34</issue>):<page-range>24157&#8211;60</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(18)35741-7</pub-id><pub-id pub-id-type="pmid">1332946</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kieser</surname><given-names>A</given-names></name><name name-style="western"><surname>Kilger</surname><given-names>E</given-names></name><name name-style="western"><surname>Gires</surname><given-names>O</given-names></name><name name-style="western"><surname>Ueffing</surname><given-names>M</given-names></name><name name-style="western"><surname>Kolch</surname><given-names>W</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>W</given-names></name></person-group>. <article-title>Epstein-Barr Virus Latent Membrane Protein-1 Triggers AP-1 Activity via the C-Jun N-Terminal Kinase Cascade</article-title>. <source>EMBO J</source> (<year>1997</year>) <volume>16</volume>(<issue>21</issue>):<page-range>6478&#8211;85</page-range>. doi: <pub-id pub-id-type="doi">10.1093/emboj/16.21.6478</pub-id><pub-id pub-id-type="pmcid">PMC1170253</pub-id><pub-id pub-id-type="pmid">9351829</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finke</surname><given-names>J</given-names></name><name name-style="western"><surname>Fritzen</surname><given-names>R</given-names></name><name name-style="western"><surname>Ternes</surname><given-names>P</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Bross</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Lange</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Expression of Bcl-2 in Burkitt&#8217;s Lymphoma Cell Lines: Induction by Latent Epstein-Barr Virus Genes</article-title>. <source>Blood</source> (<year>1992</year>) <volume>80</volume>(<issue>2</issue>):<page-range>459&#8211;69</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V80.2.459.459</pub-id><pub-id pub-id-type="pmid">1378321</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>S</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>M</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>C</given-names></name><name name-style="western"><surname>Croom-Carter</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Induction of Bcl-2 Expression by Epstein-Barr Virus Latent Membrane Protein 1 Protects Infected B Cells From Programmed Cell Death</article-title>. <source>Cell</source> (<year>1991</year>) <volume>65</volume>(<issue>7</issue>):<page-range>1107&#8211;15</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0092-8674(91)90007-L</pub-id><pub-id pub-id-type="pmid">1648447</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>M</given-names></name><name name-style="western"><surname>Lundgren</surname><given-names>E</given-names></name></person-group>. <article-title>Expression of the Epstein Barr Virus Transforming Protein LMP1 Causes a Rapid and Transient Stimulation of the Bcl-2 Homologue Mcl-1 Levels in B-Cell Lines</article-title>. <source>Cancer Res</source> (<year>1996</year>) <volume>56</volume>(<issue>20</issue>):<page-range>4610&#8211;3</page-range>.<pub-id pub-id-type="pmid">8840972</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldwell</surname><given-names>RG</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RC</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name></person-group>. <article-title>Epstein-Barr Virus LMP2A-Induced B-Cell Survival in Two Unique Classes of EmuLMP2A Transgenic Mice</article-title>. <source>J Virol</source> (<year>2000</year>) <volume>74</volume>(<issue>3</issue>):<page-range>1101&#8211;13</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.74.3.1101-1113.2000</pub-id><pub-id pub-id-type="pmcid">PMC111444</pub-id><pub-id pub-id-type="pmid">10627520</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuda</surname><given-names>M</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name></person-group>. <article-title>Epstein-Barr Virus Latent Membrane Protein 2A Mediates Transformation Through Constitutive Activation of the Ras/PI3-K/Akt Pathway</article-title>. <source>J Virol</source> (<year>2007</year>) <volume>81</volume>(<issue>17</issue>):<page-range>9299&#8211;306</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00537-07</pub-id><pub-id pub-id-type="pmcid">PMC1951437</pub-id><pub-id pub-id-type="pmid">17582000</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moody</surname><given-names>CA</given-names></name><name name-style="western"><surname>Scott</surname><given-names>RS</given-names></name><name name-style="western"><surname>Amirghahari</surname><given-names>N</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>CO</given-names></name><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>CW</given-names></name><etal/></person-group>. <article-title>Modulation of the Cell Growth Regulator mTOR by Epstein-Barr Virus-Encoded LMP2A</article-title>. <source>J Virol</source> (<year>2005</year>) <volume>79</volume>(<issue>9</issue>):<page-range>5499&#8211;506</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.79.9.5499-5506.2005</pub-id><pub-id pub-id-type="pmcid">PMC1082717</pub-id><pub-id pub-id-type="pmid">15827164</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldwell</surname><given-names>RG</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>JB</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name></person-group>. <article-title>Epstein-Barr Virus LMP2A Drives B Cell Development and Survival in the Absence of Normal B Cell Receptor Signals</article-title>. <source>Immunity</source> (<year>1998</year>) <volume>9</volume>(<issue>3</issue>):<page-range>405&#8211;11</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80623-8</pub-id><pub-id pub-id-type="pmid">9768760</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merchant</surname><given-names>M</given-names></name><name name-style="western"><surname>Swart</surname><given-names>R</given-names></name><name name-style="western"><surname>Katzman</surname><given-names>RB</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>A</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The Effects of the Epstein-Barr Virus Latent Membrane Protein 2A on B Cell Function</article-title>. <source>Int Rev Immunol</source> (<year>2001</year>) <volume>20</volume>(<issue>6</issue>):<page-range>805&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.3109/08830180109045591</pub-id><pub-id pub-id-type="pmid">11913951</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaganti</surname><given-names>S</given-names></name><name name-style="western"><surname>Bell</surname><given-names>AI</given-names></name><name name-style="western"><surname>Pastor</surname><given-names>NB</given-names></name><name name-style="western"><surname>Milner</surname><given-names>AE</given-names></name><name name-style="western"><surname>Drayson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Epstein-Barr Virus Infection In Vitro can Rescue Germinal Center B Cells With Inactivated Immunoglobulin Genes</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>13</issue>):<page-range>4249&#8211;52</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2005-06-2327</pub-id><pub-id pub-id-type="pmid">16123211</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bechtel</surname><given-names>D</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>J</given-names></name><name name-style="western"><surname>Unkel</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuppers</surname><given-names>R</given-names></name></person-group>. <article-title>Transformation of BCR-Deficient Germinal-Center B Cells by EBV Supports a Major Role of the Virus in the Pathogenesis of Hodgkin and Posttransplantation Lymphomas</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>13</issue>):<page-range>4345&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2005-06-2342</pub-id><pub-id pub-id-type="pmid">16131568</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancao</surname><given-names>C</given-names></name><name name-style="western"><surname>Altmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Jungnickel</surname><given-names>B</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>W</given-names></name></person-group>. <article-title>Rescue of "Crippled" Germinal Center B Cells From Apoptosis by Epstein-Barr Virus</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>13</issue>):<page-range>4339&#8211;44</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2005-06-2341</pub-id><pub-id pub-id-type="pmcid">PMC1895254</pub-id><pub-id pub-id-type="pmid">16076866</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancao</surname><given-names>C</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>W</given-names></name></person-group>. <article-title>Epstein-Barr Virus Latent Membrane Protein 2A is a B-Cell Receptor Mimic and Essential for B-Cell Survival</article-title>. <source>Blood</source> (<year>2007</year>) <volume>110</volume>(<issue>10</issue>):<page-range>3715&#8211;21</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2007-05-090142</pub-id><pub-id pub-id-type="pmcid">PMC2077319</pub-id><pub-id pub-id-type="pmid">17682125</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portis</surname><given-names>T</given-names></name><name name-style="western"><surname>Dyck</surname><given-names>P</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name></person-group>. <article-title>Epstein-Barr Virus (EBV) LMP2A Induces Alterations in Gene Transcription Similar to Those Observed in Reed-Sternberg Cells of Hodgkin Lymphoma</article-title>. <source>Blood</source> (<year>2003</year>) <volume>102</volume>(<issue>12</issue>):<page-range>4166&#8211;78</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2003-04-1018</pub-id><pub-id pub-id-type="pmid">12907455</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vockerodt</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>E</given-names></name><name name-style="western"><surname>Prouzova</surname><given-names>Z</given-names></name><name name-style="western"><surname>Schrader</surname><given-names>A</given-names></name><name name-style="western"><surname>Kube</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Suppression of the LMP2A Target Gene, EGR-1, Protects Hodgkin&#8217;s Lymphoma Cells From Entry to the EBV Lytic Cycle</article-title>. <source>J Pathol</source> (<year>2013</year>) <volume>230</volume>(<issue>4</issue>):<fpage>399</fpage>&#8211;<lpage>409</lpage>. doi: <pub-id pub-id-type="doi">10.1002/path.4198</pub-id><pub-id pub-id-type="pmid">23592216</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Ko</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JE</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Park</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification</article-title>. <source>J Pathol Transl Med</source> (<year>2017</year>) <volume>51</volume>(<issue>4</issue>):<page-range>352&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.4132/jptm.2017.03.15</pub-id><pub-id pub-id-type="pmcid">PMC5525035</pub-id><pub-id pub-id-type="pmid">28592786</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>M</given-names></name></person-group>. <article-title>Management of Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disease in Recipients of Solid Organ Transplantation</article-title>. <source>Am J Transplant</source> (<year>2001</year>) <volume>1</volume>(<issue>2</issue>):<page-range>103&#8211;8</page-range>.<pub-id pub-id-type="pmid">12099356</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nijland</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Pals</surname><given-names>ST</given-names></name><name name-style="western"><surname>Bemelman</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Ten Berge</surname><given-names>IJ</given-names></name></person-group>. <article-title>Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management</article-title>. <source>Transplant Direct</source> (<year>2016</year>) <volume>2</volume>(<issue>1</issue>):<fpage>e48</fpage>. doi: <pub-id pub-id-type="doi">10.1097/TXD.0000000000000557</pub-id><pub-id pub-id-type="pmid">27500242</pub-id><pub-id pub-id-type="pmcid">PMC4946499</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stojanova</surname><given-names>J</given-names></name><name name-style="western"><surname>Caillard</surname><given-names>S</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>A</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P</given-names></name></person-group>. <article-title>Post-Transplant Lymphoproliferative Disease (PTLD): Pharmacological, Virological and Other Determinants</article-title>. <source>Pharmacol Res</source> (<year>2011</year>) <volume>63</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phrs.2010.10.016</pub-id><pub-id pub-id-type="pmid">21056103</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snow</surname><given-names>AL</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>OM</given-names></name></person-group>. <article-title>Epstein-Barr Virus: Evasive Maneuvers in the Development of PTLD</article-title>. <source>Am J Transplant</source> (<year>2007</year>) <volume>7</volume>(<issue>2</issue>):<page-range>271&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-6143.2006.01650.x</pub-id><pub-id pub-id-type="pmid">17229074</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guedan</surname><given-names>S</given-names></name><name name-style="western"><surname>Ruella</surname><given-names>M</given-names></name><name name-style="western"><surname>June</surname><given-names>CH</given-names></name></person-group>. <article-title>Emerging Cellular Therapies for Cancer</article-title>. <source>Annu Rev Immunol</source> (<year>2019</year>) <volume>37</volume>:<page-range>145&#8211;71</page-range>. doi: <pub-id pub-id-type="doi">10.1146/annurev-immunol-042718-041407</pub-id><pub-id pub-id-type="pmcid">PMC7399614</pub-id><pub-id pub-id-type="pmid">30526160</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carle</surname><given-names>LN</given-names></name><name name-style="western"><surname>Ko</surname><given-names>CC</given-names></name><name name-style="western"><surname>Castle</surname><given-names>JT</given-names></name></person-group>. <article-title>Nasopharyngeal Carcinoma</article-title>. <source>Head Neck Pathol</source> (<year>2012</year>) <volume>6</volume>(<issue>3</issue>):<page-range>364&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s12105-012-0333-z</pub-id><pub-id pub-id-type="pmcid">PMC3422589</pub-id><pub-id pub-id-type="pmid">22323116</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>MC</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>JM</given-names></name></person-group>. <article-title>Epidemiology of Nasopharyngeal Carcinoma</article-title>. <source>Semin Cancer Biol</source> (<year>2002</year>) <volume>12</volume>(<issue>6</issue>):<page-range>421&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1044579X02000858</pub-id><pub-id pub-id-type="pmid">12450728</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>ET</given-names></name><name name-style="western"><surname>Adami</surname><given-names>HO</given-names></name></person-group>. <article-title>The Enigmatic Epidemiology of Nasopharyngeal Carcinoma</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> (<year>2006</year>) <volume>15</volume>(<issue>10</issue>):<page-range>1765&#8211;77</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0353</pub-id><pub-id pub-id-type="pmid">17035381</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Micheau</surname><given-names>C</given-names></name><name name-style="western"><surname>Rilke</surname><given-names>F</given-names></name><name name-style="western"><surname>Pilotti</surname><given-names>S</given-names></name></person-group>. <article-title>Proposal for a New Histopathological Classification of the Carcinomas of the Nasopharynx</article-title>. <source>Tumori</source> (<year>1978</year>) <volume>64</volume>(<issue>5</issue>):<page-range>513&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1177/030089167806400509</pub-id><pub-id pub-id-type="pmid">746599</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshizaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wakisaka</surname><given-names>N</given-names></name><name name-style="western"><surname>Murono</surname><given-names>S</given-names></name><name name-style="western"><surname>Endo</surname><given-names>K</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Pathogenic Role of Epstein-Barr Virus Latent Membrane Protein-1 in the Development of Nasopharyngeal Carcinoma</article-title>. <source>Cancer Lett</source> (<year>2013</year>) <volume>337</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.canlet.2013.05.018</pub-id><pub-id pub-id-type="pmid">23689138</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banko</surname><given-names>AV</given-names></name><name name-style="western"><surname>Lazarevic</surname><given-names>IB</given-names></name><name name-style="western"><surname>Folic</surname><given-names>MM</given-names></name><name name-style="western"><surname>Djukic</surname><given-names>VB</given-names></name><name name-style="western"><surname>Cirkovic</surname><given-names>AM</given-names></name><name name-style="western"><surname>Karalic</surname><given-names>DZ</given-names></name><etal/></person-group>. <article-title>Characterization of the Variability of Epstein-Barr Virus Genes in Nasopharyngeal Biopsies: Potential Predictors for Carcinoma Progression</article-title>. <source>PloS One</source> (<year>2016</year>) <volume>11</volume>(<issue>4</issue>):<fpage>e0153498</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0153498</pub-id><pub-id pub-id-type="pmid">27071030</pub-id><pub-id pub-id-type="pmcid">PMC4829223</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raab-Traub</surname><given-names>N</given-names></name></person-group>. <article-title>Nasopharyngeal Carcinoma: An Evolving Role for the Epstein-Barr Virus</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2015</year>) <volume>390</volume>(<issue>Pt 1</issue>):<page-range>339&#8211;63</page-range>. doi: <pub-id pub-id-type="doi">10.1007/978-3-319-22822-8_14</pub-id><pub-id pub-id-type="pmid">26424653</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>P</given-names></name><name name-style="western"><surname>Leahy</surname><given-names>L</given-names></name><name name-style="western"><surname>Thorley-Lawson</surname><given-names>DA</given-names></name></person-group>. <article-title>The Epstein-Barr Virus Encoded BART miRNAs Potentiate Tumor Growth <italic toggle="yes">In Vivo</italic>
</article-title>. <source>PloS Pathog</source> (<year>2015</year>) <volume>11</volume>(<issue>1</issue>):<fpage>e1004561</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1004561</pub-id><pub-id pub-id-type="pmid">25590614</pub-id><pub-id pub-id-type="pmcid">PMC4295875</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosmopoulos</surname><given-names>K</given-names></name><name name-style="western"><surname>Pegtel</surname><given-names>M</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>J</given-names></name><name name-style="western"><surname>Moffett</surname><given-names>H</given-names></name><name name-style="western"><surname>Novina</surname><given-names>C</given-names></name><name name-style="western"><surname>Middeldorp</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Comprehensive Profiling of Epstein-Barr Virus microRNAs in Nasopharyngeal Carcinoma</article-title>. <source>J Virol</source> (<year>2009</year>) <volume>83</volume>(<issue>5</issue>):<page-range>2357&#8211;67</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.02104-08</pub-id><pub-id pub-id-type="pmcid">PMC2643705</pub-id><pub-id pub-id-type="pmid">19091858</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fotheringham</surname><given-names>JA</given-names></name><name name-style="western"><surname>Coalson</surname><given-names>NE</given-names></name><name name-style="western"><surname>Raab-Traub</surname><given-names>N</given-names></name></person-group>. <article-title>Epstein-Barr Virus Latent Membrane Protein-2A Induces ITAM/Syk- and Akt-Dependent Epithelial Migration Through Alphav-Integrin Membrane Translocation</article-title>. <source>J Virol</source> (<year>2012</year>) <volume>86</volume>(<issue>19</issue>):<page-range>10308&#8211;20</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00853-12</pub-id><pub-id pub-id-type="pmcid">PMC3457296</pub-id><pub-id pub-id-type="pmid">22837212</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pegtel</surname><given-names>DM</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>A</given-names></name><name name-style="western"><surname>Sheen</surname><given-names>TS</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>CH</given-names></name><name name-style="western"><surname>Golub</surname><given-names>TR</given-names></name><name name-style="western"><surname>Thorley-Lawson</surname><given-names>DA</given-names></name></person-group>. <article-title>Epstein-Barr-Virus-Encoded LMP2A Induces Primary Epithelial Cell Migration and Invasion: Possible Role in Nasopharyngeal Carcinoma Metastasis</article-title>. <source>J Virol</source> (<year>2005</year>) <volume>79</volume>(<issue>24</issue>):<page-range>15430&#8211;42</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.79.24.15430-15442.2005</pub-id><pub-id pub-id-type="pmcid">PMC1316046</pub-id><pub-id pub-id-type="pmid">16306614</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornburg</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Pathmanathan</surname><given-names>R</given-names></name><name name-style="western"><surname>Raab-Traub</surname><given-names>N</given-names></name></person-group>. <article-title>Activation of Nuclear factor-kappaB P50 Homodimer/Bcl-3 Complexes in Nasopharyngeal Carcinoma</article-title>. <source>Cancer Res</source> (<year>2003</year>) <volume>63</volume>(<issue>23</issue>):<page-range>8293&#8211;301</page-range>.<pub-id pub-id-type="pmid">14678988</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukayama</surname><given-names>M</given-names></name><name name-style="western"><surname>Ushiku</surname><given-names>T</given-names></name></person-group>. <article-title>Epstein-Barr Virus-Associated Gastric Carcinoma</article-title>. <source>Pathol Res Pract</source> (<year>2011</year>) <volume>207</volume>(<issue>9</issue>):<page-range>529&#8211;37</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.prp.2011.07.004</pub-id><pub-id pub-id-type="pmid">21944426</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KM</given-names></name></person-group>. <article-title>Pathology of Epstein-Barr Virus-Associated Gastric Carcinoma and Its Relationship to Prognosis</article-title>. <source>Gut Liver</source> (<year>2011</year>) <volume>5</volume>(<issue>2</issue>):<page-range>143&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.5009/gnl.2011.5.2.143</pub-id><pub-id pub-id-type="pmcid">PMC3140657</pub-id><pub-id pub-id-type="pmid">21814592</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Beek</surname><given-names>J</given-names></name><name name-style="western"><surname>zur Hausen</surname><given-names>A</given-names></name><name name-style="western"><surname>Klein Kranenbarg</surname><given-names>E</given-names></name><name name-style="western"><surname>van de Velde</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Middeldorp</surname><given-names>JM</given-names></name><name name-style="western"><surname>van den Brule</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node Involvement</article-title>. <source>J Clin Oncol</source> (<year>2004</year>) <volume>22</volume>(<issue>4</issue>):<page-range>664&#8211;70</page-range>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2004.08.061</pub-id><pub-id pub-id-type="pmid">14966089</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>J</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>C</given-names></name><name name-style="western"><surname>Malta</surname><given-names>M</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>H</given-names></name></person-group>. <article-title>Epstein-Barr Virus Gene Expression and Latency Pattern in Gastric Carcinomas: A Systematic Review</article-title>. <source>Future Oncol</source> (<year>2017</year>) <volume>13</volume>(<issue>6</issue>):<page-range>567&#8211;79</page-range>. doi: <pub-id pub-id-type="doi">10.2217/fon-2016-0475</pub-id><pub-id pub-id-type="pmid">28118740</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research N</collab></person-group>. <article-title>Comprehensive Molecular Characterization of Gastric Adenocarcinoma</article-title>. <source>Nature</source> (<year>2014</year>) <volume>513</volume>(<issue>7517</issue>):<page-range>202&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature13480</pub-id><pub-id pub-id-type="pmcid">PMC4170219</pub-id><pub-id pub-id-type="pmid">25079317</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaneda</surname><given-names>A</given-names></name><name name-style="western"><surname>Fukayama</surname><given-names>M</given-names></name></person-group>. <article-title>Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations</article-title>. <source>Pathobiology</source> (<year>2015</year>) <volume>82</volume>(<issue>5</issue>):<page-range>212&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1159/000434683</pub-id><pub-id pub-id-type="pmid">26337667</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaneda</surname><given-names>A</given-names></name><name name-style="western"><surname>Matsusaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Aburatani</surname><given-names>H</given-names></name><name name-style="western"><surname>Fukayama</surname><given-names>M</given-names></name></person-group>. <article-title>Epstein-Barr Virus Infection as an Epigenetic Driver of Tumorigenesis</article-title>. <source>Cancer Res</source> (<year>2012</year>) <volume>72</volume>(<issue>14</issue>):<page-range>3445&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3919</pub-id><pub-id pub-id-type="pmid">22761333</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKay</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>V</given-names></name><name name-style="western"><surname>Duggan</surname><given-names>T</given-names></name><name name-style="western"><surname>Tremlett</surname><given-names>H</given-names></name></person-group>. <article-title>Risk Factors Associated With the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review</article-title>. <source>BioMed Res Int</source> (<year>2015</year>) <volume>2015</volume>:<fpage>817238</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2015/817238</pub-id><pub-id pub-id-type="pmid">25802867</pub-id><pub-id pub-id-type="pmcid">PMC4329850</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ascherio</surname><given-names>A</given-names></name><name name-style="western"><surname>Munger</surname><given-names>KL</given-names></name></person-group>. <article-title>Epstein-Barr Virus Infection and Multiple Sclerosis: A Review</article-title>. <source>J Neuroimmune Pharmacol</source> (<year>2010</year>) <volume>5</volume>(<issue>3</issue>):<page-range>271&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11481-010-9201-3</pub-id><pub-id pub-id-type="pmid">20369303</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jons</surname><given-names>D</given-names></name><name name-style="western"><surname>Sundstrom</surname><given-names>P</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>O</given-names></name></person-group>. <article-title>Targeting Epstein-Barr Virus Infection as an Intervention Against Multiple Sclerosis</article-title>. <source>Acta Neurol Scand</source> (<year>2015</year>) <volume>131</volume>(<issue>2</issue>):<fpage>69</fpage>&#8211;<lpage>79</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ane.12294</pub-id><pub-id pub-id-type="pmid">25208981</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pender</surname><given-names>MP</given-names></name><name name-style="western"><surname>Csurhes</surname><given-names>PA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>NL</given-names></name><name name-style="western"><surname>Neller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>KK</given-names></name><etal/></person-group>. <article-title>Epstein-Barr Virus-Specific T Cell Therapy for Progressive Multiple Sclerosis</article-title>. <source>JCI Insight</source> (<year>2018</year>) <volume>3</volume>(<issue>22</issue>). doi: <pub-id pub-id-type="doi">10.1172/jci.insight.124714</pub-id><pub-id pub-id-type="pmcid">PMC6302936</pub-id><pub-id pub-id-type="pmid">30429369</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polepole</surname><given-names>P</given-names></name><name name-style="western"><surname>Bartenslager</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Petro</surname><given-names>TM</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>Epstein-Barr Virus-Immortalized B Lymphocytes Exacerbate Experimental Autoimmune Encephalomyelitis in Xenograft Mice</article-title>. <source>J Med Virol</source> (<year>2021</year>) <volume>93</volume>(<issue>6</issue>):<page-range>3813&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jmv.26188</pub-id><pub-id pub-id-type="pmcid">PMC7738365</pub-id><pub-id pub-id-type="pmid">32543727</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zdimerova</surname><given-names>H</given-names></name><name name-style="western"><surname>Murer</surname><given-names>A</given-names></name><name name-style="western"><surname>Engelmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Raykova</surname><given-names>A</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gujer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Attenuated Immune Control of Epstein-Barr Virus in Humanized Mice is Associated With the Multiple Sclerosis Risk Factor HLA-Dr15</article-title>. <source>Eur J Immunol</source> (<year>2021</year>) <volume>51</volume>(<issue>1</issue>):<fpage>64</fpage>&#8211;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1002/eji.202048655</pub-id><pub-id pub-id-type="pmid">32949466</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>TR</given-names></name><name name-style="western"><surname>Rostgaard</surname><given-names>K</given-names></name><name name-style="western"><surname>Askling</surname><given-names>J</given-names></name><name name-style="western"><surname>Steffensen</surname><given-names>R</given-names></name><name name-style="western"><surname>Oturai</surname><given-names>A</given-names></name><name name-style="western"><surname>Jersild</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effects of Infectious Mononucleosis and HLA-DRB1*15 in Multiple Sclerosis</article-title>. <source>Mult Scler</source> (<year>2009</year>) <volume>15</volume>(<issue>4</issue>):<page-range>431&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1177/1352458508100037</pub-id><pub-id pub-id-type="pmid">19153174</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Martel</surname><given-names>C</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>S</given-names></name><name name-style="western"><surname>Vignat</surname><given-names>J</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Forman</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis</article-title>. <source>Lancet Oncol</source> (<year>2012</year>) <volume>13</volume>(<issue>6</issue>):<page-range>607&#8211;15</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(12)70137-7</pub-id><pub-id pub-id-type="pmid">22575588</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Randle</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>JK</given-names></name></person-group>. <article-title>Protection of Cottontop Tamarins Against Epstein-Barr Virus-Induced Malignant Lymphoma by a Prototype Subunit Vaccine</article-title>. <source>Nature</source> (<year>1985</year>) <volume>318</volume>(<issue>6043</issue>):<page-range>287&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1038/318287a0</pub-id><pub-id pub-id-type="pmid">2999604</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emini</surname><given-names>EA</given-names></name><name name-style="western"><surname>Schleif</surname><given-names>WA</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>ME</given-names></name><name name-style="western"><surname>Silberklang</surname><given-names>M</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>LD</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Antigenic Analysis of the Epstein-Barr Virus Major Membrane Antigen (Gp350/220) Expressed in Yeast and Mammalian Cells: Implications for the Development of a Subunit Vaccine</article-title>. <source>Virology</source> (<year>1988</year>) <volume>166</volume>(<issue>2</issue>):<page-range>387&#8211;93</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0042-6822(88)90509-0</pub-id><pub-id pub-id-type="pmid">2845652</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Lovgren</surname><given-names>K</given-names></name><name name-style="western"><surname>Scullion</surname><given-names>FT</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B</given-names></name></person-group>. <article-title>Prevention of Epstein-Barr (EB) Virus-Induced Lymphoma in Cottontop Tamarins by Vaccination With the EB Virus Envelope Glycoprotein Gp340 Incorporated Into Immune-Stimulating Complexes</article-title>. <source>J Gen Virol</source> (<year>1988</year>) <volume>69</volume>(<issue> Pt 8</issue>):<page-range>2093&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-69-8-2093</pub-id><pub-id pub-id-type="pmid">2841417</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Mackett</surname><given-names>M</given-names></name><name name-style="western"><surname>Arrand</surname><given-names>JR</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PE</given-names></name><name name-style="western"><surname>Tarlton</surname><given-names>J</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name></person-group>. <article-title>Immunization of Cottontop Tamarins and Rabbits With a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein Gp340 and Alum</article-title>. <source>Vaccine</source> (<year>1994</year>) <volume>12</volume>(<issue>13</issue>):<page-range>1180&#8211;4</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0264-410X(94)90240-2</pub-id><pub-id pub-id-type="pmid">7839721</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackman</surname><given-names>WT</given-names></name><name name-style="western"><surname>Mann</surname><given-names>KA</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Spaete</surname><given-names>RR</given-names></name></person-group>. <article-title>Expression of Epstein-Barr Virus Gp350 as a Single Chain Glycoprotein for an EBV Subunit Vaccine</article-title>. <source>Vaccine</source> (<year>1999</year>) <volume>17</volume>(<issue>7-8</issue>):<page-range>660&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0264-410X(98)00248-5</pub-id><pub-id pub-id-type="pmid">10067671</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokal</surname><given-names>EM</given-names></name><name name-style="western"><surname>Hoppenbrouwers</surname><given-names>K</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>C</given-names></name><name name-style="western"><surname>Moutschen</surname><given-names>M</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>P</given-names></name><name name-style="western"><surname>Moreels</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Recombinant Gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein-Barr Virus Vaccine in Healthy Young Adults</article-title>. <source>J Infect Dis</source> (<year>2007</year>) <volume>196</volume>(<issue>12</issue>):<page-range>1749&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1086/523813</pub-id><pub-id pub-id-type="pmid">18190254</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sen</surname><given-names>G</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>G</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>DH</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>A Novel Tetrameric Gp350 1-470 as a Potential Epstein-Barr Virus Vaccine</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>(<issue>30</issue>):<page-range>3039&#8211;45</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.04.071</pub-id><pub-id pub-id-type="pmcid">PMC3700395</pub-id><pub-id pub-id-type="pmid">23665339</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanekiyo</surname><given-names>M</given-names></name><name name-style="western"><surname>Bu</surname><given-names>W</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Meng</surname><given-names>G</given-names></name><name name-style="western"><surname>Whittle</surname><given-names>JR</given-names></name><name name-style="western"><surname>Baxa</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site</article-title>. <source>Cell</source> (<year>2015</year>) <volume>162</volume>(<issue>5</issue>):<page-range>1090&#8211;100</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2015.07.043</pub-id><pub-id pub-id-type="pmcid">PMC4757492</pub-id><pub-id pub-id-type="pmid">26279189</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Arjunaraja</surname><given-names>S</given-names></name><name name-style="western"><surname>Snow</surname><given-names>AL</given-names></name><name name-style="western"><surname>Snapper</surname><given-names>CM</given-names></name></person-group>. <article-title>Rabbits Immunized With Epstein-Barr Virus Gh/gL or gB Recombinant Proteins Elicit Higher Serum Virus Neutralizing Activity Than Gp350</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>(<issue>34</issue>):<page-range>4050&#8211;5</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.06.021</pub-id><pub-id pub-id-type="pmid">27291087</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Krummenacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Song</surname><given-names>S</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Immunization With Fc-Based Recombinant Epstein-Barr Virus Gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>932</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.00932</pub-id><pub-id pub-id-type="pmid">29765376</pub-id><pub-id pub-id-type="pmcid">PMC5938345</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu</surname><given-names>W</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H</given-names></name><name name-style="western"><surname>Banh</surname><given-names>DV</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>F</given-names></name><name name-style="western"><surname>Tariq</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Immunization With Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells</article-title>. <source>Immunity</source> (<year>2019</year>) <volume>50</volume>(<issue>5</issue>):<fpage>1305</fpage>&#8211;<lpage>16 e6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.010</pub-id><pub-id pub-id-type="pmid">30979688</pub-id><pub-id pub-id-type="pmcid">PMC6660903</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S</given-names></name><name name-style="western"><surname>Imadome</surname><given-names>KI</given-names></name><name name-style="western"><surname>Snapper</surname><given-names>CM</given-names></name></person-group>. <article-title>Immunization With Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice From Lethal Dose EBV Challenge</article-title>. <source>Vaccines (Basel)</source> (<year>2021</year>) <volume>9</volume>(<issue>3</issue>). doi: <pub-id pub-id-type="doi">10.3390/vaccines9030285</pub-id><pub-id pub-id-type="pmcid">PMC8003492</pub-id><pub-id pub-id-type="pmid">33808755</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiss</surname><given-names>R</given-names></name><name name-style="western"><surname>Jochum</surname><given-names>S</given-names></name><name name-style="western"><surname>Wanner</surname><given-names>G</given-names></name><name name-style="western"><surname>Reisbach</surname><given-names>G</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>W</given-names></name><name name-style="western"><surname>Zeidler</surname><given-names>R</given-names></name></person-group>. <article-title>A Virus-Like Particle-Based Epstein-Barr Virus Vaccine</article-title>. <source>J Virol</source> (<year>2011</year>) <volume>85</volume>(<issue>24</issue>):<page-range>13105&#8211;13</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.05598-11</pub-id><pub-id pub-id-type="pmcid">PMC3233152</pub-id><pub-id pub-id-type="pmid">21994444</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Zyl</surname><given-names>DG</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>MH</given-names></name><name name-style="western"><surname>Shumilov</surname><given-names>A</given-names></name><name name-style="western"><surname>Schneidt</surname><given-names>V</given-names></name><name name-style="western"><surname>Poirey</surname><given-names>R</given-names></name><name name-style="western"><surname>Schlehe</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Immunogenic Particles With a Broad Antigenic Spectrum Stimulate Cytolytic T Cells and Offer Increased Protection Against EBV Infection <italic toggle="yes">Ex Vivo</italic> and in Mice</article-title>. <source>PloS Pathog</source> (<year>2018</year>) <volume>14</volume>(<issue>12</issue>):<fpage>e1007464</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1007464</pub-id><pub-id pub-id-type="pmid">30521644</pub-id><pub-id pub-id-type="pmcid">PMC6298685</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogembo</surname><given-names>JG</given-names></name><name name-style="western"><surname>Muraswki</surname><given-names>MR</given-names></name><name name-style="western"><surname>McGinnes</surname><given-names>LW</given-names></name><name name-style="western"><surname>Parcharidou</surname><given-names>A</given-names></name><name name-style="western"><surname>Sutiwisesak</surname><given-names>R</given-names></name><name name-style="western"><surname>Tison</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A Chimeric EBV Gp350/220-Based VLP Replicates the Virion B-Cell Attachment Mechanism and Elicits Long-Lasting Neutralizing Antibodies in Mice</article-title>. <source>J Transl Med</source> (<year>2015</year>) <volume>13</volume>:<fpage>50</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-015-0415-2</pub-id><pub-id pub-id-type="pmid">25885535</pub-id><pub-id pub-id-type="pmcid">PMC4328182</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>EM</given-names></name><name name-style="western"><surname>Foley</surname><given-names>J</given-names></name><name name-style="western"><surname>Tison</surname><given-names>T</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R</given-names></name><name name-style="western"><surname>Ogembo</surname><given-names>JG</given-names></name></person-group>. <article-title>Novel Epstein-Barr Virus-Like Particles Incorporating Gh/gL-EBNA1 or gB-LMP2 Induce High Neutralizing Antibody Titers and EBV-Specific T-Cell Responses in Immunized Mice</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>8</volume>(<issue>12</issue>):<page-range>19255&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.13770</pub-id><pub-id pub-id-type="pmcid">PMC5386682</pub-id><pub-id pub-id-type="pmid">27926486</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moutschen</surname><given-names>M</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>P</given-names></name><name name-style="western"><surname>Sokal</surname><given-names>EM</given-names></name><name name-style="western"><surname>Smets</surname><given-names>F</given-names></name><name name-style="western"><surname>Haumont</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazzu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Phase I/II Studies to Evaluate Safety and Immunogenicity of a Recombinant Gp350 Epstein-Barr Virus Vaccine in Healthy Adults</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>(<issue>24</issue>):<page-range>4697&#8211;705</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.008</pub-id><pub-id pub-id-type="pmid">17485150</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janz</surname><given-names>A</given-names></name><name name-style="western"><surname>Oezel</surname><given-names>M</given-names></name><name name-style="western"><surname>Kurzeder</surname><given-names>C</given-names></name><name name-style="western"><surname>Mautner</surname><given-names>J</given-names></name><name name-style="western"><surname>Pich</surname><given-names>D</given-names></name><name name-style="western"><surname>Kost</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Infectious Epstein-Barr Virus Lacking Major Glycoprotein BLLF1 (Gp350/220) Demonstrates the Existence of Additional Viral Ligands</article-title>. <source>J Virol</source> (<year>2000</year>) <volume>74</volume>(<issue>21</issue>):<page-range>10142&#8211;52</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.74.21.10142-10152.2000</pub-id><pub-id pub-id-type="pmcid">PMC102053</pub-id><pub-id pub-id-type="pmid">11024143</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draper</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Angov</surname><given-names>E</given-names></name><name name-style="western"><surname>Horii</surname><given-names>T</given-names></name><name name-style="western"><surname>Miller</surname><given-names>LH</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>P</given-names></name><name name-style="western"><surname>Theisen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Recent Advances in Recombinant Protein-Based Malaria Vaccines</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>(<issue>52</issue>):<page-range>7433&#8211;43</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.093</pub-id><pub-id pub-id-type="pmcid">PMC4687528</pub-id><pub-id pub-id-type="pmid">26458807</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hjerrild</surname><given-names>KA</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><name name-style="western"><surname>Wright</surname><given-names>KE</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RE</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JM</given-names></name><name name-style="western"><surname>Labbe</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>Production of Full-Length Soluble Plasmodium Falciparum RH5 Protein Vaccine Using a Drosophila Melanogaster Schneider 2 Stable Cell Line System</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>30357</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep30357</pub-id><pub-id pub-id-type="pmid">27457156</pub-id><pub-id pub-id-type="pmcid">PMC4960544</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diamond</surname><given-names>DJ</given-names></name><name name-style="western"><surname>La Rosa</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiuppesi</surname><given-names>F</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>H</given-names></name><name name-style="western"><surname>Dadwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Wussow</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>A Fifty-Year Odyssey: Prospects for a Cytomegalovirus Vaccine in Transplant and Congenital Infection</article-title>. <source>Expert Rev Vaccines</source> (<year>2018</year>) <volume>17</volume>(<issue>10</issue>):<fpage>889</fpage>&#8211;<lpage>911</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14760584.2018.1526085</pub-id><pub-id pub-id-type="pmid">30246580</pub-id><pub-id pub-id-type="pmcid">PMC6343505</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Snapper</surname><given-names>CM</given-names></name></person-group>. <article-title>Development of Novel Vaccines Against Human Cytomegalovirus</article-title>. <source>Hum Vaccin Immunother</source> (<year>2019</year>) <volume>15</volume>(<issue>11</issue>):<page-range>2673&#8211;83</page-range>. doi: <pub-id pub-id-type="doi">10.1080/21645515.2019.1593729</pub-id><pub-id pub-id-type="pmcid">PMC6930071</pub-id><pub-id pub-id-type="pmid">31017831</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>RB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Murata</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Novel Trimeric Human Cytomegalovirus Glycoprotein B Elicits a High-Titer Neutralizing Antibody Response</article-title>. <source>Vaccine</source> (<year>2018</year>) <volume>36</volume>(<issue>37</issue>):<page-range>5580&#8211;90</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.07.056</pub-id><pub-id pub-id-type="pmcid">PMC6556890</pub-id><pub-id pub-id-type="pmid">30082162</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Adler</surname><given-names>SP</given-names></name><name name-style="western"><surname>McVoy</surname><given-names>MA</given-names></name><name name-style="western"><surname>Snapper</surname><given-names>CM</given-names></name></person-group>. <article-title>Immunization With Human Cytomegalovirus Core Fusion Machinery and Accessory Envelope Proteins Elicit Strong Synergistic Neutralizing Activities</article-title>. <source>Vaccines (Basel)</source> (<year>2020</year>) <volume>8</volume>(<issue>2</issue>). doi: <pub-id pub-id-type="doi">10.3390/vaccines8020179</pub-id><pub-id pub-id-type="pmcid">PMC7348949</pub-id><pub-id pub-id-type="pmid">32294946</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname></name><name name-style="western"><surname>Xinle</surname></name><name name-style="western"><surname>Snapper</surname></name><name name-style="western"><surname>Clifford</surname><given-names>M</given-names></name></person-group>. <article-title>Vaccine Compositions of Herpesvirus Envelope Protein Combinations to Induce Immune Response</article-title>. <source>USPTO</source> (<year>2021</year>) <volume>20210163542</volume>.</mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>JM</given-names></name><name name-style="western"><surname>Long</surname><given-names>HM</given-names></name><name name-style="western"><surname>Tierney</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Shannon-Lowe</surname><given-names>C</given-names></name><name name-style="western"><surname>Leese</surname><given-names>AM</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Early T Cell Recognition of B Cells Following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination</article-title>. <source>PloS Pathog</source> (<year>2016</year>) <volume>12</volume>(<issue>4</issue>):<fpage>e1005549</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1005549</pub-id><pub-id pub-id-type="pmid">27096949</pub-id><pub-id pub-id-type="pmcid">PMC4838210</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adhikary</surname><given-names>D</given-names></name><name name-style="western"><surname>Behrends</surname><given-names>U</given-names></name><name name-style="western"><surname>Moosmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Witter</surname><given-names>K</given-names></name><name name-style="western"><surname>Bornkamm</surname><given-names>GW</given-names></name><name name-style="western"><surname>Mautner</surname><given-names>J</given-names></name></person-group>. <article-title>Control of Epstein-Barr Virus Infection In Vitro by T Helper Cells Specific for Virion Glycoproteins</article-title>. <source>J Exp Med</source> (<year>2006</year>) <volume>203</volume>(<issue>4</issue>):<fpage>995</fpage>&#8211;<lpage>1006</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.20051287</pub-id><pub-id pub-id-type="pmid">16549597</pub-id><pub-id pub-id-type="pmcid">PMC2118290</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forni</surname><given-names>G</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name></person-group>. <article-title>Covid-19 Commission of Accademia Nazionale Dei Lincei R. COVID-19 Vaccines: Where We Stand and Challenges Ahead</article-title>. <source>Cell Death Differ</source> (<year>2021</year>) <volume>28</volume>(<issue>2</issue>):<page-range>626&#8211;39</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41418-020-00720-9</pub-id><pub-id pub-id-type="pmcid">PMC7818063</pub-id><pub-id pub-id-type="pmid">33479399</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriakidis</surname><given-names>NC</given-names></name><name name-style="western"><surname>Lopez-Cortes</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>EV</given-names></name><name name-style="western"><surname>Grimaldos</surname><given-names>AB</given-names></name><name name-style="western"><surname>Prado</surname><given-names>EO</given-names></name></person-group>. <article-title>SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3 Candidates</article-title>. <source>NPJ Vaccines</source> (<year>2021</year>) <volume>6</volume>(<issue>1</issue>):<fpage>28</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-021-00292-w</pub-id><pub-id pub-id-type="pmid">33619260</pub-id><pub-id pub-id-type="pmcid">PMC7900244</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name><name name-style="western"><surname>Bickham</surname><given-names>KL</given-names></name><name name-style="western"><surname>Subklewe</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>ML</given-names></name><name name-style="western"><surname>Chahroudi</surname><given-names>A</given-names></name><name name-style="western"><surname>Kurilla</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Human CD4(+) T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen EBNA1</article-title>. <source>J Exp Med</source> (<year>2000</year>) <volume>191</volume>(<issue>10</issue>):<page-range>1649&#8211;60</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.191.10.1649</pub-id><pub-id pub-id-type="pmcid">PMC2193162</pub-id><pub-id pub-id-type="pmid">10811859</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>T</given-names></name><name name-style="western"><surname>Voo</surname><given-names>KS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RF</given-names></name></person-group>. <article-title>Critical Role of EBNA1-Specific CD4+ T Cells in the Control of Mouse Burkitt Lymphoma <italic toggle="yes">In Vivo</italic>
</article-title>. <source>J Clin Invest</source> (<year>2004</year>) <volume>114</volume>(<issue>4</issue>):<page-range>542&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI22053</pub-id><pub-id pub-id-type="pmcid">PMC503775</pub-id><pub-id pub-id-type="pmid">15314691</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tellam</surname><given-names>J</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>G</given-names></name><name name-style="western"><surname>Green</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Miles</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Moss</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>Endogenous Presentation of CD8+ T Cell Epitopes From Epstein-Barr Virus-Encoded Nuclear Antigen 1</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>199</volume>(<issue>10</issue>):<page-range>1421&#8211;31</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20040191</pub-id><pub-id pub-id-type="pmcid">PMC2211806</pub-id><pub-id pub-id-type="pmid">15148340</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>L</given-names></name><name name-style="western"><surname>Yao</surname><given-names>QY</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name></person-group>. <article-title>Epstein-Barr Virus Latent Gene Transcription in Nasopharyngeal Carcinoma Cells: Coexpression of EBNA1, LMP1, and LMP2 Transcripts</article-title>. <source>J Virol</source> (<year>1992</year>) <volume>66</volume>(<issue>5</issue>):<page-range>2689&#8211;97</page-range>. doi: <pub-id pub-id-type="doi">10.1128/jvi.66.5.2689-2697.1992</pub-id><pub-id pub-id-type="pmcid">PMC241023</pub-id><pub-id pub-id-type="pmid">1313894</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SP</given-names></name><name name-style="western"><surname>Tierney</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>WA</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name></person-group>. <article-title>Conserved CTL Epitopes Within EBV Latent Membrane Protein 2: A Potential Target for CTL-Based Tumor Therapy</article-title>. <source>J Immunol</source> (<year>1997</year>) <volume>158</volume>(<issue>7</issue>):<page-range>3325&#8211;34</page-range>.<pub-id pub-id-type="pmid">9120290</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straathof</surname><given-names>KC</given-names></name><name name-style="western"><surname>Leen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Buza</surname><given-names>EL</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>G</given-names></name><name name-style="western"><surname>Huls</surname><given-names>MH</given-names></name><name name-style="western"><surname>Heslop</surname><given-names>HE</given-names></name><etal/></person-group>. <article-title>Characterization of Latent Membrane Protein 2 Specificity in CTL Lines From Patients With EBV-Positive Nasopharyngeal Carcinoma and Lymphoma</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>175</volume>(<issue>6</issue>):<page-range>4137&#8211;47</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.175.6.4137</pub-id><pub-id pub-id-type="pmid">16148164</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Fogg</surname><given-names>M</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Daley</surname><given-names>H</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>J</given-names></name><name name-style="western"><surname>Posner</surname><given-names>MR</given-names></name><etal/></person-group>. <article-title>Epstein-Barr Virus-Specific Adoptive Immunotherapy for Recurrent, Metastatic Nasopharyngeal Carcinoma</article-title>. <source>Cancer</source> (<year>2017</year>) <volume>123</volume>(<issue>14</issue>):<page-range>2642&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cncr.30541</pub-id><pub-id pub-id-type="pmid">28222215</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Song</surname><given-names>D</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name></person-group>. <article-title>Delayed-Type Hypersensitivity (DTH) Immune Response Related With EBV-DNA in Nasopharyngeal Carcinoma Treated With Autologous Dendritic Cell Vaccination After Radiotherapy</article-title>. <source>J Immunother</source> (<year>2013</year>) <volume>36</volume>(<issue>3</issue>):<page-range>208&#8211;14</page-range>. doi: <pub-id pub-id-type="doi">10.1097/CJI.0b013e31828bd87b</pub-id><pub-id pub-id-type="pmid">23502768</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Si</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lan</surname><given-names>G</given-names></name><name name-style="western"><surname>Du</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Si</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The Safety and Immunological Effects of Rad5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up</article-title>. <source>Chem Pharm Bull (Tokyo)</source> (<year>2016</year>) <volume>64</volume>(<issue>8</issue>):<page-range>1118&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1248/cpb.c16-00114</pub-id><pub-id pub-id-type="pmid">27477649</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>EP</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>GS</given-names></name><name name-style="western"><surname>Jia</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>BB</given-names></name><name name-style="western"><surname>Chan</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ho</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients</article-title>. <source>Cancer Res</source> (<year>2013</year>) <volume>73</volume>(<issue>6</issue>):<page-range>1676&#8211;88</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2448</pub-id><pub-id pub-id-type="pmcid">PMC6485495</pub-id><pub-id pub-id-type="pmid">23348421</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>GS</given-names></name><name name-style="western"><surname>Jia</surname><given-names>H</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>LW</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J</given-names></name><name name-style="western"><surname>Ladell</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients With EBV-Positive Cancer</article-title>. <source>Clin Cancer Res</source> (<year>2014</year>) <volume>20</volume>(<issue>19</issue>):<page-range>5009&#8211;22</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1122-T</pub-id><pub-id pub-id-type="pmcid">PMC4340506</pub-id><pub-id pub-id-type="pmid">25124688</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>CL</given-names></name><name name-style="western"><surname>Lo</surname><given-names>WF</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TH</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>SL</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>YF</given-names></name><etal/></person-group>. <article-title>Immunization With Epstein-Barr Virus (EBV) Peptide-Pulsed Dendritic Cells Induces Functional CD8+ T-Cell Immunity and may Lead to Tumor Regression in Patients With EBV-Positive Nasopharyngeal Carcinoma</article-title>. <source>Cancer Res</source> (<year>2002</year>) <volume>62</volume>(<issue>23</issue>):<page-range>6952&#8211;8</page-range>.<pub-id pub-id-type="pmid">12460912</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>GS</given-names></name><name name-style="western"><surname>Haigh</surname><given-names>TA</given-names></name><name name-style="western"><surname>Gudgeon</surname><given-names>NH</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SP</given-names></name><name name-style="western"><surname>Steven</surname><given-names>NM</given-names></name><etal/></person-group>. <article-title>Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma</article-title>. <source>J Virol</source> (<year>2004</year>) <volume>78</volume>(<issue>2</issue>):<page-range>768&#8211;78</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.78.2.768-778.2004</pub-id><pub-id pub-id-type="pmcid">PMC368843</pub-id><pub-id pub-id-type="pmid">14694109</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coghill</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bu</surname><given-names>W</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>WL</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Lou</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>High Levels of Antibody That Neutralize B-Cell Infection of Epstein-Barr Virus and That Bind EBV Gp350 Are Associated With a Lower Risk of Nasopharyngeal Carcinoma</article-title>. <source>Clin Cancer Res</source> (<year>2016</year>) <volume>22</volume>(<issue>14</issue>):<page-range>3451&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2299</pub-id><pub-id pub-id-type="pmcid">PMC4947430</pub-id><pub-id pub-id-type="pmid">26920891</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulos</surname><given-names>EB</given-names></name><name name-style="western"><surname>Ladanyi</surname><given-names>M</given-names></name><name name-style="western"><surname>Emanuel</surname><given-names>D</given-names></name><name name-style="western"><surname>Mackinnon</surname><given-names>S</given-names></name><name name-style="western"><surname>Boulad</surname><given-names>F</given-names></name><name name-style="western"><surname>Carabasi</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders After Allogeneic Bone Marrow Transplantation</article-title>. <source>N Engl J Med</source> (<year>1994</year>) <volume>330</volume>(<issue>17</issue>):<page-range>1185&#8211;91</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJM199404283301703</pub-id><pub-id pub-id-type="pmid">8093146</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanna</surname><given-names>R</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S</given-names></name><name name-style="western"><surname>Sherritt</surname><given-names>M</given-names></name><name name-style="western"><surname>Galbraith</surname><given-names>A</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>SR</given-names></name><name name-style="western"><surname>Rafter</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Activation and Adoptive Transfer of Epstein-Barr Virus-Specific Cytotoxic T Cells in Solid Organ Transplant Patients With Posttransplant Lymphoproliferative Disease</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>1999</year>) <volume>96</volume>(<issue>18</issue>):<page-range>10391&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.96.18.10391</pub-id><pub-id pub-id-type="pmcid">PMC17898</pub-id><pub-id pub-id-type="pmid">10468618</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savoldo</surname><given-names>B</given-names></name><name name-style="western"><surname>Goss</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>MM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>T</given-names></name><name name-style="western"><surname>Gee</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Treatment of Solid Organ Transplant Recipients With Autologous Epstein Barr Virus-Specific Cytotoxic T Lymphocytes (CTLs)</article-title>. <source>Blood</source> (<year>2006</year>) <volume>108</volume>(<issue>9</issue>):<page-range>2942&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2006-05-021782</pub-id><pub-id pub-id-type="pmcid">PMC1895521</pub-id><pub-id pub-id-type="pmid">16835376</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comoli</surname><given-names>P</given-names></name><name name-style="western"><surname>Labirio</surname><given-names>M</given-names></name><name name-style="western"><surname>Basso</surname><given-names>S</given-names></name><name name-style="western"><surname>Baldanti</surname><given-names>F</given-names></name><name name-style="western"><surname>Grossi</surname><given-names>P</given-names></name><name name-style="western"><surname>Furione</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Infusion of Autologous Epstein-Barr Virus (EBV)-Specific Cytotoxic T Cells for Prevention of EBV-Related Lymphoproliferative Disorder in Solid Organ Transplant Recipients With Evidence of Active Virus Replication</article-title>. <source>Blood</source> (<year>2002</year>) <volume>99</volume>(<issue>7</issue>):<page-range>2592&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V99.7.2592</pub-id><pub-id pub-id-type="pmid">11895798</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comoli</surname><given-names>P</given-names></name><name name-style="western"><surname>Pedrazzoli</surname><given-names>P</given-names></name><name name-style="western"><surname>Maccario</surname><given-names>R</given-names></name><name name-style="western"><surname>Basso</surname><given-names>S</given-names></name><name name-style="western"><surname>Carminati</surname><given-names>O</given-names></name><name name-style="western"><surname>Labirio</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes</article-title>. <source>J Clin Oncol</source> (<year>2005</year>) <volume>23</volume>(<issue>35</issue>):<page-range>8942&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2005.02.6195</pub-id><pub-id pub-id-type="pmid">16204009</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louis</surname><given-names>CU</given-names></name><name name-style="western"><surname>Straathof</surname><given-names>K</given-names></name><name name-style="western"><surname>Bollard</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ennamuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Gerken</surname><given-names>C</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>TT</given-names></name><etal/></person-group>. <article-title>Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma</article-title>. <source>J&#160;Immunother</source> (<year>2010</year>) <volume>33</volume>(<issue>9</issue>):<page-range>983&#8211;90</page-range>. doi: <pub-id pub-id-type="doi">10.1097/CJI.0b013e3181f3cbf4</pub-id><pub-id pub-id-type="pmcid">PMC2964409</pub-id><pub-id pub-id-type="pmid">20948438</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chia</surname><given-names>WK</given-names></name><name name-style="western"><surname>Teo</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Ang</surname><given-names>SF</given-names></name><name name-style="western"><surname>Tai</surname><given-names>WM</given-names></name><etal/></person-group>. <article-title>Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma</article-title>. <source>Mol Ther</source> (<year>2014</year>) <volume>22</volume>(<issue>1</issue>):<page-range>132&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1038/mt.2013.242</pub-id><pub-id pub-id-type="pmcid">PMC3978790</pub-id><pub-id pub-id-type="pmid">24297049</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bollard</surname><given-names>CM</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>S</given-names></name><name name-style="western"><surname>Torrano</surname><given-names>V</given-names></name><name name-style="western"><surname>Diouf</surname><given-names>O</given-names></name><name name-style="western"><surname>Ku</surname><given-names>S</given-names></name><name name-style="western"><surname>Hazrat</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins</article-title>. <source>J Clin Oncol</source> (<year>2014</year>) <volume>32</volume>(<issue>8</issue>):<fpage>798</fpage>&#8211;<lpage>808</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2013.51.5304</pub-id><pub-id pub-id-type="pmid">24344220</pub-id><pub-id pub-id-type="pmcid">PMC3940538</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Parsonage</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>X</given-names></name><name name-style="western"><surname>Machado</surname><given-names>LR</given-names></name><name name-style="western"><surname>James</surname><given-names>CH</given-names></name><name name-style="western"><surname>Salman</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-Cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma</article-title>. <source>Cancer Immunol Res</source> (<year>2015</year>) <volume>3</volume>(<issue>10</issue>):<page-range>1138&#8211;47</page-range>. doi: <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0203-T</pub-id><pub-id pub-id-type="pmcid">PMC4456157</pub-id><pub-id pub-id-type="pmid">25711537</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>HI</given-names></name><name name-style="western"><surname>Kim</surname><given-names>UH</given-names></name><name name-style="western"><surname>Shin</surname><given-names>AR</given-names></name><name name-style="western"><surname>Won</surname><given-names>JN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>A Novel Epstein-Barr Virus-Latent Membrane Protein-1-Specific T-Cell Receptor for TCR Gene Therapy</article-title>. <source>Br J Cancer</source> (<year>2018</year>) <volume>118</volume>(<issue>4</issue>):<page-range>534&#8211;45</page-range>. doi: <pub-id pub-id-type="doi">10.1038/bjc.2017.475</pub-id><pub-id pub-id-type="pmcid">PMC5830600</pub-id><pub-id pub-id-type="pmid">29360818</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells <italic toggle="yes">In Vitro</italic> And <italic toggle="yes">In Vivo</italic>
</article-title>. <source>Onco Targets Ther</source> (<year>2019</year>) <volume>12</volume>:<page-range>9341&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.2147/OTT.S221040</pub-id><pub-id pub-id-type="pmcid">PMC6847990</pub-id><pub-id pub-id-type="pmid">31807014</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>T Cells Expressing a LMP1-Specific Chimeric Antigen Receptor Mediate Antitumor Effects Against LMP1-Positive Nasopharyngeal Carcinoma Cells <italic toggle="yes">In Vitro</italic> and <italic toggle="yes">In Vivo</italic>
</article-title>. <source>J BioMed Res</source> (<year>2014</year>) <volume>28</volume>(<issue>6</issue>):<page-range>468&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.7555/JBR.28.20140066</pub-id><pub-id pub-id-type="pmcid">PMC4250525</pub-id><pub-id pub-id-type="pmid">25469116</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roskrow</surname><given-names>MA</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>N</given-names></name><name name-style="western"><surname>Gan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sixbey</surname><given-names>JW</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CY</given-names></name><name name-style="western"><surname>Kimbrough</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Treatment of Patients With EBV-Positive Relapsed Hodgkin&#8217;s Disease</article-title>. <source>Blood</source> (<year>1998</year>) <volume>91</volume>(<issue>8</issue>):<page-range>2925&#8211;34</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.V91.8.2925.2925_2925_2934</pub-id><pub-id pub-id-type="pmid">9531603</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V</given-names></name><name name-style="western"><surname>Schuessler</surname><given-names>A</given-names></name><name name-style="western"><surname>Beagley</surname><given-names>L</given-names></name><name name-style="western"><surname>Rehan</surname><given-names>S</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Pre-Emptive and Therapeutic Adoptive Immunotherapy for Nasopharyngeal Carcinoma: Phenotype and Effector Function of T Cells Impact on Clinical Response</article-title>. <source>Oncoimmunology</source> (<year>2017</year>) <volume>6</volume>(<issue>2</issue>):<fpage>e1273311</fpage>. doi: <pub-id pub-id-type="doi">10.1080/2162402X.2016.1273311</pub-id><pub-id pub-id-type="pmid">28344888</pub-id><pub-id pub-id-type="pmcid">PMC5353921</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottschalk</surname><given-names>S</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>OL</given-names></name><name name-style="western"><surname>Sili</surname><given-names>U</given-names></name><name name-style="western"><surname>Huls</surname><given-names>MH</given-names></name><name name-style="western"><surname>Goltsova</surname><given-names>T</given-names></name><name name-style="western"><surname>Davis</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Generating CTLs Against the Subdominant Epstein-Barr Virus LMP1 Antigen for the Adoptive Immunotherapy of EBV-Associated Malignancies</article-title>. <source>Blood</source> (<year>2003</year>) <volume>101</volume>(<issue>5</issue>):<page-range>1905&#8211;12</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2002-05-1514</pub-id><pub-id pub-id-type="pmid">12411306</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagarsheth</surname><given-names>NB</given-names></name><name name-style="western"><surname>Norberg</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sinkoe</surname><given-names>AL</given-names></name><name name-style="western"><surname>Adhikary</surname><given-names>S</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Lack</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>TCR-Engineered T Cells Targeting E7 for Patients With Metastatic HPV-Associated Epithelial Cancers</article-title>. <source>Nat Med</source> (<year>2021</year>) <volume>27</volume>(<issue>3</issue>):<page-range>419&#8211;25</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41591-020-01225-1</pub-id><pub-id pub-id-type="pmcid">PMC9620481</pub-id><pub-id pub-id-type="pmid">33558725</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manfredi</surname><given-names>F</given-names></name><name name-style="western"><surname>Cianciotti</surname><given-names>BC</given-names></name><name name-style="western"><surname>Potenza</surname><given-names>A</given-names></name><name name-style="western"><surname>Tassi</surname><given-names>E</given-names></name><name name-style="western"><surname>Noviello</surname><given-names>M</given-names></name><name name-style="western"><surname>Biondi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1689</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01689</pub-id><pub-id pub-id-type="pmid">33013822</pub-id><pub-id pub-id-type="pmcid">PMC7494743</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>YJ</given-names></name></person-group>. <article-title>Engineered T Cell Therapy for Cancer in the Clinic</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2250</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.02250</pub-id><pub-id pub-id-type="pmid">31681259</pub-id><pub-id pub-id-type="pmcid">PMC6798078</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orentas</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Roskopf</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>GP</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>MI</given-names></name></person-group>. <article-title>Retroviral Transduction of a T Cell Receptor Specific for an Epstein-Barr Virus-Encoded Peptide</article-title>. <source>Clin Immunol</source> (<year>2001</year>) <volume>98</volume>(<issue>2</issue>):<page-range>220&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1006/clim.2000.4977</pub-id><pub-id pub-id-type="pmid">11161978</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaft</surname><given-names>N</given-names></name><name name-style="western"><surname>Lankiewicz</surname><given-names>B</given-names></name><name name-style="western"><surname>Drexhage</surname><given-names>J</given-names></name><name name-style="western"><surname>Berrevoets</surname><given-names>C</given-names></name><name name-style="western"><surname>Moss</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Levitsky</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>T Cell Re-Targeting to EBV Antigens Following TCR Gene Transfer: CD28-Containing Receptors Mediate Enhanced Antigen-Specific IFNgamma Production</article-title>. <source>Int Immunol</source> (<year>2006</year>) <volume>18</volume>(<issue>4</issue>):<fpage>591</fpage>&#8211;<lpage>601</lpage>. doi: <pub-id pub-id-type="doi">10.1093/intimm/dxh401</pub-id><pub-id pub-id-type="pmid">16507598</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>E</given-names></name><name name-style="western"><surname>Mizukoshi</surname><given-names>E</given-names></name><name name-style="western"><surname>Kishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Hamana</surname><given-names>H</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A New Cloning and Expression System Yields and Validates TCRs From Blood Lymphocytes of Patients With Cancer Within 10 Days</article-title>. <source>Nat Med</source> (<year>2013</year>) <volume>19</volume>(<issue>11</issue>):<page-range>1542&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm.3358</pub-id><pub-id pub-id-type="pmid">24121927</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Mu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Evaluation of Epstein-Barr Virus Latent Membrane Protein 2 Specific T-Cell Receptors Driven by T-Cell Specific Promoters Using Lentiviral Vector</article-title>. <source>Clin Dev Immunol</source> (<year>2011</year>) <volume>2011</volume>:<fpage>716926</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2011/716926</pub-id><pub-id pub-id-type="pmid">21969838</pub-id><pub-id pub-id-type="pmcid">PMC3182378</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name></person-group>. <article-title>Redirecting T Cells Against Epstein-Barr Virus Infection and Associated Oncogenesis</article-title>. <source>Cells</source> (<year>2020</year>) <volume>9</volume>(<issue>6</issue>). doi: <pub-id pub-id-type="doi">10.3390/cells9061400</pub-id><pub-id pub-id-type="pmcid">PMC7349826</pub-id><pub-id pub-id-type="pmid">32512847</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghorashian</surname><given-names>S</given-names></name><name name-style="western"><surname>Barros</surname><given-names>RD</given-names></name><name name-style="western"><surname>Pospori</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Human MHC Class I-Restricted High Avidity CD4(+) T Cells Generated by Co-Transfer of TCR and CD8 Mediate Efficient Tumor Rejection <italic toggle="yes">In Vivo</italic>
</article-title>. <source>Oncoimmunology</source> (<year>2013</year>) <volume>2</volume>(<issue>1</issue>):<fpage>e22590</fpage>. doi: <pub-id pub-id-type="doi">10.4161/onci.22590</pub-id><pub-id pub-id-type="pmid">23483821</pub-id><pub-id pub-id-type="pmcid">PMC3583927</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Holler</surname><given-names>A</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>N</given-names></name><name name-style="western"><surname>Azzi</surname><given-names>T</given-names></name><name name-style="western"><surname>Vanoaica</surname><given-names>LD</given-names></name><etal/></person-group>. <article-title>CD8+ T Cells Retain Protective Functions Despite Sustained Inhibitory Receptor Expression During Epstein-Barr Virus Infection <italic toggle="yes">In Vivo</italic>
</article-title>. <source>PloS Pathog</source> (<year>2019</year>) <volume>15</volume>(<issue>5</issue>):<fpage>e1007748</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1007748</pub-id><pub-id pub-id-type="pmid">31145756</pub-id><pub-id pub-id-type="pmcid">PMC6542544</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savoldo</surname><given-names>B</given-names></name><name name-style="western"><surname>Rooney</surname><given-names>CM</given-names></name><name name-style="western"><surname>Di Stasi</surname><given-names>A</given-names></name><name name-style="western"><surname>Abken</surname><given-names>H</given-names></name><name name-style="western"><surname>Hombach</surname><given-names>A</given-names></name><name name-style="western"><surname>Foster</surname><given-names>AE</given-names></name><etal/></person-group>. <article-title>Epstein Barr Virus Specific Cytotoxic T Lymphocytes Expressing the Anti-CD30zeta Artificial Chimeric T-Cell Receptor for Immunotherapy of Hodgkin Disease</article-title>. <source>Blood</source> (<year>2007</year>) <volume>110</volume>(<issue>7</issue>):<page-range>2620&#8211;30</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2006-11-059139</pub-id><pub-id pub-id-type="pmcid">PMC1988944</pub-id><pub-id pub-id-type="pmid">17507664</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>CR</given-names></name><name name-style="western"><surname>Micklethwaite</surname><given-names>KP</given-names></name><name name-style="western"><surname>Savoldo</surname><given-names>B</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>CA</given-names></name><name name-style="western"><surname>Lam</surname><given-names>S</given-names></name><name name-style="western"><surname>Ku</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Infusion of Donor-Derived CD19-Redirected Virus-Specific T Cells for B-Cell Malignancies Relapsed After Allogeneic Stem Cell Transplant: A Phase 1 Study</article-title>. <source>Blood</source> (<year>2013</year>) <volume>122</volume>(<issue>17</issue>):<page-range>2965&#8211;73</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2013-06-506741</pub-id><pub-id pub-id-type="pmcid">PMC3811171</pub-id><pub-id pub-id-type="pmid">24030379</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fousek</surname><given-names>K</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>J</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>SK</given-names></name><name name-style="western"><surname>George</surname><given-names>A</given-names></name><name name-style="western"><surname>An</surname><given-names>X</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>TT</given-names></name><etal/></person-group>. <article-title>CAR T-Cells That Target Acute B-Lineage Leukemia Irrespective of CD19 Expression</article-title>. <source>Leukemia</source> (<year>2021</year>) <volume>35</volume>(<issue>1</issue>):<fpage>75</fpage>&#8211;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41375-020-0792-2</pub-id><pub-id pub-id-type="pmid">32205861</pub-id><pub-id pub-id-type="pmcid">PMC7519582</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>E</given-names></name><name name-style="western"><surname>Marin</surname><given-names>D</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>P</given-names></name><name name-style="western"><surname>Macapinlac</surname><given-names>HA</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P</given-names></name><name name-style="western"><surname>Basar</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors</article-title>. <source>N Engl J Med</source> (<year>2020</year>) <volume>382</volume>(<issue>6</issue>):<page-range>545&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1910607</pub-id><pub-id pub-id-type="pmcid">PMC7101242</pub-id><pub-id pub-id-type="pmid">32023374</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>J</given-names></name><name name-style="western"><surname>Goy</surname><given-names>A</given-names></name><name name-style="western"><surname>Locke</surname><given-names>FL</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>CA</given-names></name><name name-style="western"><surname>Hill</surname><given-names>BT</given-names></name><etal/></person-group>. <article-title>KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma</article-title>. <source>N Engl J Med</source> (<year>2020</year>) <volume>382</volume>(<issue>14</issue>):<page-range>1331&#8211;42</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1914347</pub-id><pub-id pub-id-type="pmcid">PMC7731441</pub-id><pub-id pub-id-type="pmid">32242358</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham-Rundles</surname><given-names>C</given-names></name></person-group>. <article-title>Common Variable Immune Deficiency: Case Studies</article-title>. <source>Blood</source> (<year>2019</year>) <volume>134</volume>(<issue>21</issue>):<page-range>1787&#8211;95</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood.2019002062</pub-id><pub-id pub-id-type="pmcid">PMC6872959</pub-id><pub-id pub-id-type="pmid">31751486</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>